Document:

Supply Agreement

 Exhibit 10.11 
 Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 SUPPLY AGREEMENT 
 This SUPPLY AGREEMENT (the “Agreement”) is made as of November 18, 2005 (the “Effective Date”) by and between CARDIOMEMS,
INC., a Delaware corporation with its principal place of business located at 75 Fifth Street, N.W., Suite 440, Atlanta, GA 30308 (“Supplier”), and MEDTRONIC, INC., a Minnesota
corporation with its principal place of business located at 710 Medtronic Parkway, Minneapolis, MN 55432 (“Purchaser”). Purchaser and Supplier may be referred to herein individually as a “Party” or collectively as
the “Parties.” 
 WITNESSETH 
 WHEREAS, Supplier has considerable experience in the design and manufacture of microelectromechanical sensors; 
 WHEREAS, pursuant to that certain License and Development Agreement of even date herewith (the “License Agreement”), Supplier has agreed to
develop a microelectromechanical sensor for use in connection with Purchaser’s implantable leads and implantable powered devices to address impaired cardiac function and/or hypertension, in return for royalties on sales of products
incorporating such sensors and payment of certain milestones; 
 WHEREAS, Purchaser wishes to purchase from Supplier a supply of such sensors
for incorporation by Purchaser into products for in human clinical studies and products for commercial sale; and 
 WHEREAS, Supplier is
willing to supply Purchaser with such sensors pursuant to the terms and conditions as set forth herein; 
 NOW, THEREFORE, in consideration
of the foregoing and the covenants and promises contained in this Agreement, Purchaser and Supplier hereby agree as follows: 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 ARTICLE 1 
 DEFINITIONS 
 As used in this Agreement, capitalized terms not otherwise defined below shall have the
meanings ascribed to such terms in the License Agreement, and the following capitalized terms shall have the following meanings: 
 1.1
“Affiliate” means, with respect to a Party, any corporation or other business entity controlling, controlled by or under common control with such Party. The term “controlling” (with correlative meanings for the terms
“controlled by” and “under common control with”) as used in this definition means either (a) possession of the direct or indirect ownership of more than fifty percent (50%) of the voting or income interest of the
applicable corporation or other business entity, or (b) the ability, by contract or otherwise, to control the management of the applicable corporation or other business entity. 
 1.2 “Certificate of Compliance” shall have the meaning set forth in Section 3.1. 
 1.3 “Change of Control” shall mean any of the following events: 
 (a) A merger, consolidation, exchange, or reorganization to which Supplier is a party if the individuals and entities who were shareholders of
Supplier immediately prior to the effective date of such transaction have, immediately following the effective date of such transaction, beneficial ownership (as defined in Rule 13d-3 under the Securities Exchange Act of 1934) of less than fifty
percent (50%) of the total combined voting power of all classes of securities issued by the surviving corporation for the election of directors of the surviving corporation; 
 (b) Approval by the shareholders of Supplier of a plan of complete liquidation of Supplier or of an agreement for the sale or disposition by
Supplier of all or substantially all Supplier’s assets; 
 (c) The sale or transfer of all or substantially all of the assets of
Supplier relating to the manufacture of any Supply Deliverable; 
  

 2. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 (d) The acquisition after the date hereof, without prior approval by the “Continuity
Directors” as such term is defined below, of direct or indirect beneficial ownership (as defined in Rule 13d-3 under the Securities Exchange Act of 1934) of securities of Supplier representing, in the aggregate, [*] or more of the total
combined voting power of all classes of Supplier’s then issued and outstanding securities by any person or entity or by a group of associated persons or entities acting in concert; 
 (e) The acquisition after the date hereof of direct or indirect beneficial ownership (as defined in Rule 13d-3 under the Securities Exchange Act
of 1934) of securities of Supplier representing, in the aggregate, more than fifty percent (50%) of the total combined voting power of all classes of Supplier’s then issued and outstanding securities by any person or entity or by a group
of associated persons or entities acting in concert; or 
 (f) A change in the composition of the Board at any time after the date
hereof such that the “Continuity Directors” cease for any reason to constitute at least a majority of the Board. For purposes of this event, “Continuity Directors” means those members of the Board who either: (i) were
directors as of the date hereof; or (ii) were elected by, or on the nomination or recommendation of, [*] of the then-existing Continuity Directors. 
 1.4 “[*] Specifications” means the specifications set forth on Exhibit A attached hereto. 
 1.5 “Confidential Information” means all information not publicly known that is disclosed by one party (“Discloser”) to the other party (“Recipient”) during the term of this Agreement (or in
contemplation of it), including, without limitation, trade secrets, know-how, and information contained in or relating to designs, specifications, drawings, processes, technology, computer programs, products, pricing, costs, finances, personnel,
suppliers, customers, markets and business and launch plans (but will not include information specifically excluded below). Disclosures may be made in any manner, including through written documents, magnetic media, electronic transmissions, verbal
disclosures, visual presentations, and facility tours. The obligations of this Agreement will apply to all information which the Recipient knows or has reason to know or believe that the Discloser considers to be Confidential 

  

 3. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
Information. Information will be excluded from Confidential Information if it (1) was already rightfully in the possession and control of the Recipient
prior to its receipt from the Discloser, (2) is independently derived by the Recipient without use of the Discloser’s Confidential Information, (3) is or becomes a matter of public knowledge (other than as a result of a disclosure by
Recipient), or (4) is required to be disclosed under operation of applicable law or regulation provided that the Recipient notifies the Discloser as soon as reasonably possible in order for the Discloser to take action to protect the
Discloser’s Confidential Information. 
 1.6 “Defective Product” shall have the meaning set forth in
Section 3.3(a). 
 1.7 “Exclusivity Period” shall have the meaning given to such term in the License Agreement.

 1.8 “FDA” means the United States Food and Drug Administration, or any successor thereto having the administrative
authority to regulate the marketing of medical devices in the United States. 
 1.9 “FD&C Act” means the United States
Food, Drug and Cosmetic Act, as amended, and any regulations promulgated thereunder. 
 1.10 “Good Manufacturing Practice”
or “GMP” means the then-current standards for the manufacture of medical devices, as set forth in the Food, Drug and Cosmetic Act, as amended, and applicable regulations and guidances promulgated thereunder, and any other laws or
regulations applicable to the manufacture of medical devices in any country. 
 1.11 “Initial Cost” shall equal the average
Manufacturing Cost of the first [*] units of Supply Deliverables delivered to Purchaser under this Agreement for use in products approved (in a form incorporating one or more Supply Deliverables) for commercial sale. 
 1.12 “Manufacturing Cost” means the sum of the following, all of which shall be calculated on a per-unit basis and in accordance with
U.S. generally accepted accounting principles consistently applied, to the extent Supplier has delivered to Purchaser a written accounting showing the amount of each component of the following and, with respect to each component of subsection
(c) below, the allocation basis and the manner in which it was calculated: 
  

 4. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 (a) The amounts paid by Supplier to a Qualified Vendor for (i) providing raw materials
and packaging materials for producing the Supply Deliverables, (ii) manufacturing, filling and/or finishing Supply Deliverables or any component thereof, (iii) transporting, storing, and insuring Supply Deliverables, and (iv) testing
Supply Deliverables, including with respect to the foregoing, all taxes (other than income taxes) and customs duty charges imposed by governmental authorities with respect thereto, in each case to the extent paid by Supplier and not reimbursed or
refunded or credited to Supplier by a Third Party, and net of amounts paid but refunded to Supplier or credited against amounts due from Supplier to Qualified Vendors (or the value of discounts or other benefits received by Supplier from Qualified
Vendors) that provide goods or services to Supplier with respect to both Supply Deliverables and other Supplier projects; 
 (b) The
direct costs and charges incurred by Supplier in connection with the manufacture, filling, finishing, testing and transportation of the Supply Deliverables, including Supplier’s direct internal costs with respect thereto; and 
 (c) A reasonable allocation of indirect labor, administration costs and facilities costs (including electricity, water, sewer, waste disposal,
insurance, storage, property taxes and depreciation over the expected life of buildings and equipment) attributable to the Supply Deliverables (provided, that in no event will such allocation include any excess over [*] of the aggregate amount of
such costs, as such costs are reflected in Supplier’s financial statements prepared in accordance with U.S. generally accepted accounting principles). 
 Notwithstanding the foregoing, no cost, charge, or expense will be included in more than one of subsections (a), (b), and (c). 
 1.13 “Purchaser Materials” means the [*] to be incorporated into the Supply Deliverables, as required by the Specifications. 
  

 5. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 1.14 “Qualified Vendor” means, with respect to a particular good or service provided
to Supplier in connection with manufacturing Supply Deliverables hereunder, a Third Party provider of such good or service that meets the requirements set forth in Section 2.10(b). 
 1.15 “Quality Control Procedures” shall have the meaning set forth in Section 3.1. 
 1.16 “Regulatory Authority” means the FDA in the United States and the equivalent regulatory authority or entity having the
responsibility, jurisdiction, and authority to approve the manufacture, use, importation, packaging, labeling, marketing, and sale of medical devices in any country other than the United States. 
 1.17 “Regulatory Standards” means (a) applicable standards of the International Standards Organization (“ISO”) and
applicable ISO-certified processes; (b) other quality standards and quality assurance plans referenced in the Specifications; (c) laws and requirements of Regulatory Authorities referenced in the Specifications; and (d) any other
applicable laws and requirements of Regulatory Authorities relating to the manufacture and supply of Supply Deliverables (or components thereof) by Supplier and Qualified Vendors and the incorporation of Supply Deliverables in medical devices within
the Field for commercial sale. Regulatory Standards shall include without limitation GMP with respect to the Supply Deliverable (but not its component parts). 
 1.18 “Specifications” shall mean the product characteristics, design requirements, processing, labeling, and packaging requirements, protocols and standards pertaining to the manufacture or supply of
the Supply Deliverables. The Specifications shall include the characteristics, requirements and standards contained in the Work Plan, subject to modification as set forth in the Work Plan. The Specifications shall be fully documented as part of the
Development Program, and may be modified and supplemented from time to time thereafter by mutual agreement of the Parties. 
 1.19
“Supply Deliverables” means those MEMS sensors and any other sensor/capsule components of Supplier’s MEMS sensor technology, as described in the final Specifications as of completion of the Development Program (or thereafter as
modified and supplemented by 

  

 6. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
mutual agreement of the Parties). No product shall be considered a Supply Deliverable unless and until the Development Program is completed pursuant to the
License Agreement. 
 1.20 “Third Party” means any entity or individual other than the Parties and their respective
Affiliates. 
 ARTICLE 2 
 SUPPLY OBLIGATIONS 
 2.1 Manufacture and Supply. Supplier agrees to manufacture (or have manufactured on its behalf
by Qualified Vendors) and supply to Purchaser the amount of Supply Deliverables set forth on purchase orders submitted by Purchaser in accordance with the provisions of Section 2.3. During the Exclusivity Period, Supplier shall supply Supply
Deliverables exclusively to Purchaser, and Supplier shall not manufacture (or have manufactured) any Supply Deliverables for the benefit of any party other than Purchaser. Purchaser shall use the Supply Deliverables supplied hereunder solely in the
Field as part of Medtronic Licensed Products and shall not re-sell or distribute such Supply Deliverables on a stand-alone basis. 
 2.2
Forecasts. No later than [*] months prior to the anticipated commercial launch date for the first Medtronic Licensed Product incorporating a Supply Deliverable, Purchaser shall provide a binding forecast of Purchaser’s requirements for the
pre-launch period (e.g., any initial stocking orders). Thereafter, no later than the commencement of each of Purchaser’s fiscal quarters (referred to herein as a “fiscal quarter”), Purchaser shall furnish Supplier with a rolling
forecast of its requirements of the Supply Deliverables for such fiscal quarter and each of the subsequent [*] fiscal quarters within the term of this Agreement. Such [*] quarter period shall be referred to herein as the “Forecast
Period.” The first fiscal quarter of any forecast for a Forecast Period shall constitute a binding order under Section 2.3 for supply of the forecast amount of the Supply Deliverables during such fiscal quarter, and the remaining three
(3) fiscal quarters of each forecast shall be treated as a non-binding estimate only. Notwithstanding the foregoing, in any fiscal quarter, Supplier shall not be required to supply hereunder more than [*] of the lesser of (a) the last
non-binding forecast with respect to such fiscal quarter; and (b) the 

  

 7. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
second-to-last non-binding forecast with respect to such fiscal quarter; provided, that Defective Product replacements supplied under Section 3.3(c) and
Supply Deliverables supplied pursuant to orders under Section 9.7 shall be ignored for purposes of determining the foregoing supply quantity obligation. In the event that orders for delivery of Supply Deliverables hereunder during a given
fiscal quarter exceed in the aggregate [*] of the applicable non-binding forecast with respect to such fiscal quarter, then the Parties shall [*] to [*] and [*] the revised forecast. In any event, and without limiting in any way Supplier’s
obligations hereunder, Supplier shall at all times use (and cause its vendors to use) commercially reasonable efforts to satisfy Purchaser’s orders for Supply Deliverables. Any and all forecasts provided by Purchaser to Supplier under this
Agreement shall be sent to Supplier’s materials planning department. 
 2.3 Orders. In conjunction with each binding forecast
described in Section 2.2, Purchaser shall, and from time to time in addition to such forecasts Purchaser may, provide to Supplier written purchase orders specifying quantities and requested delivery date(s) of Supply Deliverables, as well as
the location(s) to which the requested Supply Deliverables are to be shipped. Each order shall be deemed to have been accepted by Supplier unless rejected by Supplier by providing Purchaser with written notice of rejection within [*] business days
after receipt; provided, however, that Supplier shall have no right to reject, and shall be deemed to have accepted, any order to the extent that (a) the aggregate quantity of Supply Deliverables ordered for delivery (pursuant to all orders
under this Section 2.3, including the binding portion of the Forecast) during the applicable quarter is within the supply quantity obligation set forth in Section 2.2; and (b) the order requests delivery of Supply Deliverables to the
specified delivery destination no earlier than [*] after the date of the order. With respect to purchase orders that request delivery of Supply Deliverables to the specified delivery destination less than [*] after the date of the order, Supplier
shall [*] and [*] to [*] such orders, but shall have no obligation to accept such orders. Any purchase orders submitted by Purchaser shall reference this Agreement and shall be governed exclusively by the terms contained herein. Any term or
condition in any purchase order, confirmation, or other document furnished by Purchaser or Supplier that is in any way inconsistent with the terms and conditions set forth in this Agreement is hereby expressly rejected. No accepted order shall be
modified or canceled except as provided herein or upon the mutual agreement of the parties. Mutually agreed change orders shall be subject to all provisions 

  

 8. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
of this Agreement, whether or not the change order so states. Purchaser may in its sole discretion by written notice to Supplier cancel orders for and
deliveries of any Supply Deliverables that are not delivered within [*] days after the delivery date specified in the accepted order or, if returned in accordance with Section 3.3(c), are not replaced within the time period specified in
Section 3.3(c). In the event of such cancellation by Purchaser, Purchaser may then make appropriate and proportional adjustments to any outstanding orders and forecasts in light of any shortfalls in supply that relate to such cancellation.

 2.4 Requirements. Unless and until Purchaser is permitted to exercise the Back-Up Manufacturing Right, Purchaser shall purchase
from Supplier one hundred percent (100%) of Purchaser’s requirements of Supply Deliverables for use in Medtronic Licensed Products in the Field, and Purchaser shall not manufacture itself, or obtain from any Affiliate or Third Party, any
Supply Deliverables for use in Medtronic Licensed Products in the Field. 
 2.5 Packaging and Labeling. All Products manufactured by
Supplier shall be packaged and labeled in accordance with the Specifications and Purchaser’s written instructions. 
 2.6
Delivery. Supplier shall have delivered to Purchaser or its designee, at the delivery destination and by the delivery date specified in such order, the specified quantity of Supply Deliverables conforming with the Specifications and that has
been manufactured in accordance with the requirements set forth in this Agreement. Supplier shall report to Purchaser the occurrence of any event within or beyond its control which is likely to affect delivery of any order of Supply Deliverables.

 2.7 Shipping; Risk of Loss. All shipments will be made FCA (Incoterms 2000) the facility located within the United States of the
Qualified Vendor that is responsible for final assembly of the Supply Deliverables, by a common carrier selected by Purchaser. Supplier shall assist Purchaser in obtaining best cost terms from such common carrier. Except as provided herein with
respect to Defective Products, risk of loss as to Product shipped to Purchaser hereunder shall pass to Purchaser or the recipient designated by Purchaser (as applicable) upon delivery of such Product to the common carrier selected by Purchaser.

  

 9. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 2.8 Purchaser Materials. [*] Purchaser and/or its agents or subcontractors shall provide
Supplier with Purchaser Materials meeting the [*] Specifications as necessary for the manufacture of Supply Deliverables. Supplier shall maintain a reasonable supply of Purchaser Materials in good condition as required to permit Supplier to satisfy
its obligations hereunder and shall notify Purchaser at least [*] days prior to the date on which additional Purchaser Materials are required to satisfy orders hereunder. Purchaser shall deliver or cause to be delivered to Supplier such quantities
of Purchaser Materials as are specified in such notice no later than the date so required. Supplier shall maintain records with respect to the amount, location and usage of Purchaser Materials supplied by Purchaser and make such records available to
Purchaser upon request. Supplier shall use the Purchaser Materials solely for the purpose of manufacturing Supply Deliverables for Purchaser. Supplier shall promptly notify Purchaser if any Purchaser Materials delivered hereunder fail to comply with
the [*] Specifications and shall at Purchaser’s request immediately make such Purchaser Materials available to a carrier selected by Purchaser for return to Purchaser at Purchaser’s expense. Any Purchaser Materials that fail to comply with
the [*] Specifications shall be replaced by Purchaser as soon as reasonably practicable and in no event later than [*] days after receipt of notice from Supplier. If, despite Supplier’s satisfaction of its obligations under this Section,
Purchaser fails to timely deliver to Supplier Purchaser Materials that comply with the [*] Specifications, Supplier’s obligation to deliver Supply Deliverables by the date specified in an order hereunder shall be tolled to the extent such
delivery of Supply Deliverables cannot be made due to shortage of Purchaser Materials. Supplier will take no action that could result in a lien on or other encumbrance of, or that could otherwise compromise Purchaser’s ownership of, Purchaser
Materials. Upon the termination or expiration of this Agreement, Supplier will return to Purchaser in good condition all Purchaser Materials not incorporated into Supply Deliverables supplied to Purchaser hereunder. 
 2.9 {intentionally omitted}. 
 2.10 Third-Party Manufacturers. 
 (a) Within [*] days after the occurrence of the event specified in
Section 4.1(b) of the License Agreement (the “Second Milestone”), Supplier shall (i) notify Purchaser in writing of the names of the Qualified Vendors that are then responsible for manufacturing 

  

 10. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
Supply Deliverables and components thereof; and (ii) deliver information and provide access to Purchaser as reasonably necessary to verify each such
manufacturer’s qualified status. At all times after [*] days after the occurrence of the Second Milestone, Supplier shall ensure that a minimum of [*] Qualified Vendors are obligated under effective written contracts (and ensure that such
Qualified Vendors are available) to manufacture and supply Supply Deliverables in quantities sufficient to satisfy Purchaser’s requirements; provided, however, that a failure by Supplier to maintain at least [*] qualified Third Party
manufacturers lasting shorter than [*] days shall not be considered to be a breach of this provision. In no event shall Supplier manufacture or assemble (or have manufactured or assembled by a third party) any Supply Deliverable, or any subcomponent
of any Supply Deliverable, (x) in any country that is embargoed by the United States, as identified by the Office of Foreign Assets Control of the U.S. Department of Treasury; or (y) by any person listed on the Prohibited Parties Lists
maintained by the U.S. Departments of Treasury, State and Commerce. Supplier shall comply in all material respects with its obligations under contracts with Qualified Vendors. 
 (b) A manufacturer’s status as a Qualified Vendor shall be determined by Purchaser in good faith, based on such manufacturer’s compliance with
Regulatory Standards and application of Purchaser’s standard vendor qualification procedures, including the following: 
 [*] 
 Purchaser shall provide written notice with respect to the qualified status of manufacturers identified by Supplier. The name of each manufacturer that qualifies as a
Qualified Vendor shall be deemed included in Exhibit B. 
 ARTICLE 3 
 QUALITY CONTROL; ACCEPTANCE AND REJECTION. 
 3.1 Quality Control.
Supplier shall maintain and follow, and shall cause its Third Party vendors to maintain and follow, a quality control and testing program that is consistent with the Regulatory Standards and the quality standards and quality assurance plans included
in the Specifications (the “Quality Control Procedures”). Supplier shall supply to Purchaser Supply Deliverables that are manufactured in accordance with Regulatory Standards. Each 

  

 11. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
shipment of Supply Deliverables delivered to Purchaser shall be accompanied by a written certificate of compliance, executed by an authorized officer of
Supplier, confirming that the Supply Deliverables were manufactured in accordance with the Specifications and Regulatory Standards (“Certificate of Compliance”). 
 3.2 Samples; Quality Control Audits. Supplier shall maintain, and shall cause its Third Party vendors to maintain, sample units for each batch of
Supply Deliverables for a period of [*] years after Supplier delivers such Supply Deliverables to Purchaser, or longer if required by law. After such time period, Supplier shall notify Purchaser prior to the destruction or disposal of any sample
units retained under this Section 3.2 and, if requested by Purchaser, Supplier shall deliver or cause to be delivered such sample units to Purchaser in lieu of such destruction or disposal, all at Purchaser’s expense. During the term of
this Agreement, Purchaser shall have the right to audit, survey, or verify the adherence of Supplier and each Third Party vendor to the Quality Control Procedures and Regulatory Standards, all at Purchaser’s expense. In addition, upon
reasonable advance written notice to Supplier, Purchaser shall have the right to have representatives or Regulatory Authorities visit the manufacturing facilities of Supplier and Third Party vendors during normal business hours to review
Supplier’s and such vendors’ manufacturing operations, to assess compliance with Quality Control Procedures and Regulatory Standards, and to discuss any related issues with Supplier’s and such vendors’ manufacturing and
management personnel. 
 3.3 Acceptance and Rejection. 
 (a) Purchaser may reject any Supply Deliverable delivered under this Agreement that does not comply with the warranties set forth in Section 6.2 (a “Defective Product”) by giving written
notice of such Defective Products to Supplier within [*] days after receipt thereof. If Purchaser fails to so notify Supplier of any Defective Product within such [*] period, Purchaser will be deemed to have accepted the Product, subject to
Section 3.3(b) and without otherwise limiting Purchaser’s remedies. 
 (b) If, within [*] days after Purchaser’s
initial acceptance, Purchaser discovers that an accepted Supply Deliverable is a Defective Product and that the nature of such defect was 

  

 12. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
not visible upon reasonable physical inspection of such product within the time period set forth in Section 3.3(a), Purchaser may revoke its acceptance
of such Defective Product by providing written notice to Supplier of such revocation. If Purchaser fails to so notify Supplier of any Defective Product within such [*] day period, Purchaser will be deemed to have irrevocably accepted the Product,
without limiting Purchaser’s remedies (i) under Section 4.5 or Article 7 or (ii) otherwise available for Supplier’s breach of the warranty set forth in Section 6.2. 
 (c) In notifying Supplier of Defective Product, Purchaser shall identify in reasonable detail the nature of the defect and Purchaser’s
determination as to the cause of the defect. Supplier shall have a reasonable opportunity, not to exceed [*] days from receipt of notification, to review any materials provided by Purchaser to substantiate the existence of a Defective Product and to
inspect its own stocks (if any) of Supply Deliverables. Supplier shall thereafter provide Purchaser with detailed written instructions to return or dispose of such Defective Product, subject to Section 3.4. If Supplier requests that Purchaser
return allegedly Defective Product, Supplier shall immediately provide a Returned Material Authorization (“RMA”) number to Purchaser. Within [*] business days of its receipt of the RMA number, Purchaser shall return to Supplier the
allegedly Defective Product, freight prepaid, in a shipping carton with the RMA number displayed on the outside of the carton. Supplier reserves the right to refuse to accept any allegedly Defective Products that do not bear an RMA number on the
outside of the carton. Purchaser shall have no obligation to pay for any Supply Deliverable that is subject to a claim of non-compliance or defect made pursuant to this Section. Subject to Section 3.4, Supplier shall, within [*] weeks and at
its expense, replace such Supply Deliverable (or, if acceptable to Purchaser, credit Purchaser with the transfer price paid by Purchaser in connection with such Supply Deliverable) and reimburse Purchaser for its costs incurred in connection with
the shipment and return of the Defective Product. Purchaser shall not have the right to return any quantity of Supply Deliverables except for Defective Products subject to and in accordance with this Section 3.3(c). 
 3.4 Independent Testing. If Supplier disagrees with Purchaser’s determination that certain units of Supply Deliverables are Defective
Product, then either Party may submit such Supply Deliverables to an independent Third Party testing service, mutually and reasonably 

  

 13. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
acceptable to both parties, for analytical testing to determine whether such Supply Deliverables are Defective Product. The Parties agree that such testing
service’s determination shall be final and determinative. The Party against whom the Third Party testing service rules shall bear all costs of the Third Party testing. 
 3.5 Specifications. Following the completion of the Development Program, if Supplier finds it necessary or desirable to change Specifications for
any Supply Deliverable, or to change the design or production processes affecting the form, fit, function, performance, or chemical composition of any Supply Deliverable, Supplier will deliver notice to Purchaser and will not implement any such
change without Purchaser’s prior written consent. If Purchaser finds it necessary or desirable to change Specifications for any Supply Deliverable, Purchaser will deliver notice to Supplier (“Purchaser’s Change Notice”). Supplier
will use [*] to make any change identified in Purchaser’s Change Notice that is in response to a regulatory or safety issue pertaining to the Supply Deliverable, and will use [*] to effect any other change identified in Purchaser’s Change
Notice. [*], and [*] shall not be included in [*] No changes to the [*] Specifications shall be permitted without the prior written approval of both Parties. 
 ARTICLE 4 
 REGULATORY MATTERS 
 4.1 Compliance with Laws. Supplier shall supply to Purchaser Supply Deliverables that are manufactured in compliance with all applicable present
and future orders, regulations, requirements and laws of any and all federal, state, provincial and local authorities and agencies of the territory or territories where such Supply Deliverables are manufactured, including without limitation all laws
and regulations of such territories applicable to the transportation, storage, use, handling and disposal of hazardous materials. Supplier shall obtain and maintain (and shall cause its vendors to obtain and maintain) all government permits,
including without limitation health, safety and environmental permits, necessary for the conduct of the actions and procedures undertaken to supply Supply Deliverables during the term of this Agreement. 
 4.2 Records. Supplier shall keep, or cause to be kept by Third Parties, complete, accurate and authentic accounts, notes, data, records and other
documentation pertaining to the 

  

 14. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
Quality Control Procedures and the manufacture, processing, testing, labeling, and storage of the Supply Deliverables, including without limitation master
production and control records, in accordance with applicable laws and regulations and as necessary to enable the sharing of manufacturing technology contemplated by the Back-Up Manufacturing Right. Supplier shall retain, or cause to be retained by
Third Parties, such records for a period of [*] years following the date of manufacture, or longer if required by law, and upon request, shall make available to Purchaser and its representatives copies of such records. After such time period,
Supplier shall notify Purchaser prior to the destruction or disposal of any records retained under this Section 4.2 and, if requested by Purchaser, Supplier shall deliver or cause to be delivered such records to Purchaser in lieu of such
destruction or disposal, all at Purchaser’s expense. 
 4.3 Customer Complaints. Purchaser shall be responsible for
(i) managing all customer complaints or product inquires with respect to Medtronic Licensed Products, (ii) reporting such complaints or inquires to Regulatory Authorities and (iii) except as otherwise provided herein, all appropriate
corrective action related thereto. Supplier shall, at Purchaser’s reasonable request, assist Purchaser in complying with Purchaser’s legal obligations pertaining to customer complaints and vigilance reporting. [*]. 
 4.4 Adverse Events. Each Party agrees to notify the other Party in a timely manner of any adverse event, technical or clinical, which involves or
may involve a Supply Deliverable supplied hereunder. Purchaser will have primary responsibility for receiving, investigating, reporting (if applicable) and responding to any adverse events relating to Medtronic Licensed Products and/or Supply
Deliverables. Supplier agrees to provide Purchaser with all assistance reasonably requested by Purchaser to investigate the possibility that a Supply Deliverable failure, defect or nonconformity caused or contributed to any adverse event, to
determine the cause of such Supply Deliverable failure, defect or nonconformity, and to develop a plan to assure that the cause of such failure, defect or nonconformity is eliminated. Purchaser shall reimburse out-of-pocket costs incurred by
Supplier in connection with such assistance, unless the adverse event is conclusively determined to have been caused by a Supply Deliverable failure, defect or nonconformity (excluding any failure, defect or nonconformity in the Purchaser Materials
or any design defect in the Supply Deliverable). 
  

 15. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 4.5 Recall. In the event that a Medtronic Licensed Product is recalled, Purchaser shall so
notify Supplier, and Supplier shall promptly provide Purchaser with such assistance in connection with such recall as may be reasonably requested by Purchaser. [*] shall [*] by [*] in connection with [*] unless [*] is [*] (excluding any [*] or any
[*]). In the event that [*] is [*] (excluding any [*] or any [*]), [*] shall [*] for [*] in connection with [*]. 
 ARTICLE 5

 PRICES AND PAYMENT. 
 5.1 Price. Purchaser shall pay Supplier a transfer price for the Supply Deliverables equal to: (a) during the Exclusivity Period, the Manufacturing Cost for such Supply Deliverables; and (b) at all other times, the lesser
of (i) [*] times ([*]) the Manufacturing Cost for such Supply Deliverables and (ii) [*] times ([*]) the Initial Cost. At all times during the term of this Agreement, Supplier shall use all reasonable efforts to minimize the amount of
Initial Cost and Manufacturing Cost with respect to all Supply Deliverables. 
 5.2 Invoice and Payment. Supplier shall provide to
Purchaser a written invoice for each shipment of Supply Deliverables delivered to Purchaser; each such invoice shall contain a an accounting of the components of Initial Cost and Manufacturing Cost (as appropriate) for such Supply Deliverables in
such detail as is reasonably necessary for Purchaser to evaluate the calculation thereof. All payments due hereunder to Supplier shall be paid in U.S. Dollars and payment terms shall be net [*] days following Purchaser’s receipt of the
applicable invoice. All payments due hereunder shall be made to an account designated by Supplier. 
 5.3 Sharing of Cost Savings.
Within [*] days after the delivery to Purchaser of the [*] unit of a Supply Deliverable for use in a product approved (in a form incorporating one or more Supply Deliverables) for commercial sale, Supplier shall calculate the Initial Cost and notify
Purchaser of such Initial Cost in writing, showing in reasonable detail the calculation of each component of such Initial Cost. Within [*] days after the end of each fiscal quarter thereafter, Supplier shall calculate the Manufacturing Cost of units
of such Supply Deliverable delivered to Purchaser during such fiscal quarter and notify Purchaser of such Manufacturing Cost in writing, showing in reasonable detail the calculation of each component of such 

  

 16. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
Manufacturing Cost (each such notification, a “Cost Notice”). Purchaser shall pay Supplier, for each such fiscal quarter, a bonus payment
calculated as follows: 
 Bonus Payment = [*], 
 where [*]. Such bonus payment shall accompany Purchaser’s royalty payment under Section 4.4 of the License Agreement if Supplier has timely delivered the notices referred to above and shall be payable no earlier than [*] days
after the date Purchaser receives a Cost Notice. No bonus payment will be owed by Purchaser (and no refund of the transfer price will be owed by Supplier) if the Manufacturing Cost is greater than the Initial Cost. 
 5.4 Records; Audit. Supplier shall maintain complete and accurate records relevant to the calculation of the Initial Cost and any Manufacturing
Cost relied on as a basis for a transfer price for Supply Deliverables or bonus payment hereunder. Records with respect to any such transfer price or bonus payment shall be retained for a period of [*] years from the date of Supplier’s invoice
or notice of payment that relies on such transfer price or bonus payment in calculating amounts due, or for any longer period of time required by applicable law. Supplier shall make such records available during reasonable business hours for
examination (but not more than once per calendar year) by an independent certified public accountant selected by Purchaser that is subject to confidentiality and non-use obligations reasonably acceptable to Supplier, for the sole purpose of
evaluating Supplier’s determination of any Initial Cost and Manufacturing Cost under this Agreement. The auditing expense shall be paid by Purchaser; provided, however, that if the audit reveals an overpayment by Purchaser in excess of [*],
Supplier shall bear and promptly reimburse Purchaser for the accounting expense. In any case, Supplier shall make any and all payments necessary to Purchaser to correct any overpayment by Purchaser. Any records or accounting information received
from Supplier or its Affiliates shall be Confidential Information of Supplier for purposes of Article 8. Results of any such audit shall be provided to both Parties, subject to Section 8. 
  

 17. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 ARTICLE 6 
 REPRESENTATIONS AND WARRANTIES. 
 6.1 Mutual Representations and Warranties. Each Party hereby
represents and warrants to the other Party as follows: 
 (a) Due Authorization. Such Party has taken all necessary action on its part
to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. 
 (b) Enforcement of
Obligations. This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms. 
 (c) No Conflict. The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder do not conflict with,
or constitute a default or require any consent under, any contractual obligation of such Party. 
 6.2 Manufacturing Warranty.
Supplier warrants to Purchaser that all Supply Deliverables supplied hereunder shall: (a) conform to the Specifications (including any shelf life or durability requirements set forth therein) as such Specifications exist as of the time of
delivery hereunder; and (b) have been manufactured in compliance with this Agreement; and (c) be free from defects in design, materials and workmanship; and (d) not be adulterated or misbranded within the meaning of the FD&C Act;
provided, however that (i) Supplier makes no warranty with respect to the Purchaser Materials; and (ii) Supplier shall have no warranty obligation under Section 6.2(a) with respect to any Supply Deliverable that is modified, altered,
transported, stored or used after the date of delivery hereunder in a manner inconsistent in any material respect with the Specifications. Except as provided in Sections 4.4 and 4.5 and Article 7, Supplier’s sole liability and Purchaser’s
sole remedy for breach of the foregoing warranty shall be limited to the actions and procedures set forth in Section 3.3(c). 
 6.3
Additional Representations and Warranties of Supplier. 
 (a) Supplier represents and warrants that no person or entity that has
been debarred by the FDA or other Regulatory Authority, or, to the best of its knowledge, is or has 

  

 18. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
been the subject of investigation or debarment proceedings by the FDA or other Regulatory Authority, will be involved in the performance of Supplier’s
obligations under this Agreement. 
 (b) Supplier represents and warrants that it has not entered, and shall not enter, into any
agreement or arrangement with any other entity that would conflict with, or prevent or in any way interfere with Supplier’s performance of its obligations pursuant to, the terms of this Agreement. 
 6.4 Disclaimer of Warranty. EXCEPT AS SET FORTH IN THIS AGREEMENT OR ANY OTHER AGREEMENT BETWEEN THE PARTIES, EACH PARTY EXPRESSLY DISCLAIMS ANY
AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
 ARTICLE 7 
 INDEMNIFICATION.

 7.1 Indemnity by Supplier. Supplier agrees to indemnify, hold harmless and defend Purchaser and its Affiliates and
sublicensees, and their respective officers, directors, employees, agents and representatives (collectively, the “Purchaser Indemnitees”) from and against and in respect of any and all demands, claims, actions or causes of action,
assessments, losses, damages, liabilities, interest and penalties, costs and expenses arising out of a Third Party claim (including, without limitation, reasonable legal fees and disbursements incurred in connection therewith, and any amounts or
expenses required to be paid or incurred in connection with any action, suit, proceeding, claim, appeal, demand, assessment or judgment) (collectively, “Losses”) resulting from, arising out of, or imposed upon or incurred by any
person to be indemnified hereunder by reason of: (a) any breach of representation, warranty, or agreement on the part of Supplier under this Agreement; (b) any negligent act or omission or willful misconduct of Supplier, its agents,
employees or its suppliers hereunder; (c) personal injury and property damages, and costs and expenses related thereto that occur during production (i.e. the formulation, fabrication, or 

  

 19. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
manufacturing) of a Supply Deliverable by or for Supplier or for claims based on violations of federal, state or local laws or regulations (including those
applicable to employee or environmental protection) in connection with such production (e.g., a claim based on Supplier’s violations of environmental standards or standards dealing with providing a safe place to work or the maintenance of
hazardous materials); or (d) personal injury, recall, adverse event or property damage resulting from the failure of a Supply Deliverable to meet any Specification or due to a defect in materials or workmanship. Notwithstanding the foregoing,
Supplier shall not be obligated hereunder to indemnify the Purchaser Indemnitees to the extent Losses result from (i) any breach of representation, warranty, or agreement on the part of Purchaser under this Agreement; (ii) the negligence
or willful misconduct of any Purchaser Indemnitee; or (iii) a defect in design, materials or workmanship in the Purchaser Materials or a failure of the Purchaser Materials to conform with the [*] Specifications; (iv) allegations that the
Purchaser Materials infringe or misappropriate the Intellectual Property of a Third Party; or (v) modification, alteration, transport, storage or use of the Supply Deliverables after the date of delivery hereunder in a manner inconsistent in
any material respect with the Specifications. 
 7.2 Indemnity by Purchaser. Purchaser agrees to indemnify, hold harmless, and defend
Supplier and its Affiliates and sublicensees, and their respective officers, directors, employees, agents and representatives (collectively, the “Supplier Indemnitees”) from and against any Losses resulting from, arising out of, or
imposed upon or incurred by any person to be indemnified hereunder by reason of: (a) personal injury, recall, adverse event or property damage resulting from use of a Purchaser device incorporating any Supply Deliverable, provided such Supply
Deliverable (exclusive of the Purchaser Materials) conformed to the Specifications and did not contain a defect in materials or workmanship; (b) a defect in design, materials or workmanship in the Purchaser Materials or a failure of the
Purchaser Materials to conform with the [*] Specifications; (c) allegations that the Purchaser Materials infringe or misappropriate the Intellectual Property of a Third Party; or (d) the modification, alteration, transport, storage or use
of the Supply Deliverables after the date of delivery hereunder in a manner inconsistent in any material respect with the Specifications. Notwithstanding the foregoing, Purchaser shall not have any obligation to indemnify the Supplier Indemnitees
with respect to any matters for which the Purchaser Indemnitees are entitled to indemnification pursuant to Section 7.1. 
  

 20. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 7.3 Indemnification Procedures. If a claim by a Third Party is made against any indemnified
party, and if the indemnified party intends to seek indemnity with respect thereto under this Article 7, such indemnified party shall promptly notify the indemnifying party of such claim; provided, however, that failure to give timely notice shall
not affect the rights of the indemnified party except to the extent the indemnifying party has been prejudiced by such failure. Except to the extent that the claim relates to patent rights of the indemnified party, in which case the Parties shall
mutually agree on the assumption of defense, the indemnifying party shall be entitled to settle or assume the defense of such claim, including the employment of counsel reasonably satisfactory to the indemnified party, as provided below. If the
indemnifying party elects to settle or defend such claim, it shall notify the indemnified party within [*] days (but in no event less than [*] days before any pleading, filing or response on behalf of the indemnified party is due) of its intent to
do so. If the indemnifying party elects not to settle or defend such claim or fails to notify the indemnified party of its election within [*] days (or such shorter period as provided above) after receipt of the indemnified party’s notice of a
claim of indemnity hereunder, the indemnified party shall have the right to contest, settle or compromise the claim without prejudice to any rights to indemnification hereunder. Regardless of which party is controlling the settlement or defense of
any claim, (i) both the indemnified party and indemnifying party shall act in good faith, (ii) the indemnifying party shall not thereby permit to exist any lien upon any asset of any indemnified party or of its Affiliates without the
consent of the indemnified party, (iii) the indemnifying party shall permit the indemnified party to participate in such settlement or defense through counsel chosen by the indemnified party, provided that all fees, costs and expenses of such
counsel in an action controlled by the indemnifying party shall be borne by the indemnified party, unless the indemnifying party and indemnified party have different available defenses to such third-party claim, in which case such fees, costs and
expenses shall be borne by the indemnifying party, and (iv) no entry of judgment or settlement of a claim may be agreed to without the written consent of both the indemnified party and the indemnifying party, which consents shall not be
unreasonably withheld (unless such judgment or settlement is solely for money damages which the indemnifying party has demonstrated an ability to pay or will have no continuing effect in any material respect on the business of the indemnified
party). So long as the indemnifying party is reasonably contesting 

  

 21. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
any such claim in good faith as permitted herein, the indemnified party shall not pay or settle any such claim. The controlling party shall deliver, or cause
to be delivered, to the other party copies of all correspondence, pleadings, motions, briefs, appeals or other written statements submitted in connection with the settlement or defense of any such claim, and timely notices of, and the right to
participate pursuant to (iii) above in any hearing or other court proceeding relating to such claim. 
 ARTICLE 8 
 CONFIDENTIALITY. 
 8.1
Confidentiality. The Parties agree that any Confidential Information of a Party disclosed by such Party to the other Party under this Agreement shall be treated the same as Confidential Information disclosed under the License Agreement and shall
be subject to the same rights and obligations of the Parties under Article 6 of the License Agreement (even following termination thereof, as provided therein). Supplier shall be permitted to disclose Purchaser’s Confidential Information on a
need-to-know basis to its Qualified Vendors who are obligated to keep such information confidential pursuant to written agreements with Supplier, provided that Supplier causes each of its Qualified Vendors who is provided access to Purchaser’s
Confidential Information to comply with Supplier’s confidentiality and non-use obligations with respect to such Confidential Information as if such Qualified Vendor were a party hereto. After the occurrence of a Triggering Event, Purchaser
shall be permitted to disclose Supplier’s Confidential Information (including any information of Suppliers’ vendors disclosed by Supplier or its vendors to Purchaser, and specifically any information placed in escrow) on a need-to-know
basis to its vendors who are obligated to keep such information confidential pursuant to written agreements with Purchaser, provided that Purchaser causes each of its vendors who is provided access to Supplier’s Confidential Information to
comply with Purchaser’s confidentiality and non-use obligations with respect to such Confidential Information as if such vendor were a party hereto. 
  

 22. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 ARTICLE 9 
 TERM AND TERMINATION. 
  
 9.1
Term. This Agreement shall commence on the Effective Date and shall continue in effect until terminated as permitted under this Article 9. Notwithstanding the foregoing, the execution by Purchaser of that certain Series C Stock Purchase
Agreement with Supplier and the purchase by Purchaser of Supplier’s Series C shares in accordance with the terms therein shall be express conditions precedent to the effectiveness of this Agreement and the Parties’ rights hereunder.

 9.2 Material Breach. Either Party shall have the right to terminate this Agreement upon written notice to the other Party if the
other Party commits any material breach of this Agreement that such breaching Party fails to cure within sixty (60) days following written notice from the nonbreaching Party specifying such breach. 
 9.3 Relationship to License Agreement. Unless the Parties otherwise agree in writing, this Agreement will terminate immediately upon the
termination of the Development Program prior to completion or the termination of the License Agreement. 
 9.4 Change of Control.
Supplier shall immediately notify Purchaser upon the occurrence of a Change of Control. [*] following the date of such notification, (a) [*] shall have the right to terminate this Agreement, effective [*] (subject to [*]), and
(b) [*] is an [*] following such Change of Control, [*] shall have the right to terminate this Agreement, effective [*] Upon such termination, Purchaser would be permitted to exercise the Back-Up Manufacturing Right. 
 9.5 Post-Exclusivity. After the expiration of the Exclusivity Period, Purchaser shall have the right to terminate this Agreement by delivering
written notice to Supplier at least sixty (60) days prior to effectiveness of termination. 
 9.6 By Supplier. Supplier shall
have the right to terminate this Agreement by delivering written notice to Supplier at least two hundred seventy (270) days prior to effectiveness of termination (subject to Purchaser’s last-time buy rights as set forth in
Section 9.8). Upon such termination, Purchaser would be permitted to exercise the Back-Up Manufacturing Right. 
  

 23. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 9.7 Surviving Obligations. Termination or expiration of this Agreement shall not
(a) affect any other rights of either Party which may have accrued up to the date of such termination or expiration (including without limitation rights under Sections 3.3, 3.4, 4.4, 4.5, 6.2, or Article 7 with respect to Supply Deliverables
delivered hereunder) or (b) relieve Purchaser of its obligation to pay to Supplier sums due in respect of product delivered prior to termination or expiration of this Agreement. The provisions of Sections 2.8 (last sentence only), 3.2, 4.2,
4.3, 4.4, 4.5, 5.4, 9.4 (last sentence only), 9.6 (last sentence only), 9.7, and 9.8, and Articles 7, 8, and 10 shall survive the termination or expiration of this Agreement. 
 9.8 Purchaser’s Last-Time Buy Rights. During the [*] days after receipt of notice of termination by Supplier pursuant to Section 9.4(a)
or during the [*] days immediately prior to effectiveness of termination by Supplier pursuant to Section 9.6, Medtronic may in its sole discretion submit a single order for Supply Deliverables, which order shall be deemed accepted by Supplier
to the extent the number of units of Supply Deliverables so ordered does not exceed, in the aggregate, [*] times the number of units of Supply Deliverables purchased by Purchaser during the [*] immediately preceding the month in which such order is
submitted. Supplier shall satisfy any such order as soon as reasonably practicable, and in any event Supplier shall deliver [*] of the number of units of Supply Deliverables ordered pursuant to this Section over a period no longer than [*] after the
date of such order and shall deliver all Supply Deliverables ordered pursuant to this Section over a period no longer than [*] after the date of such order. Any order pursuant to this Section shall be ignored for purposes of Supplier’s [*]
supply quantity limit pursuant to Article 2. 
 ARTICLE 10 
 GENERAL TERMS. 
 10.1 Governing Law; Dispute Resolution. 
 (a) This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without reference to the choice of law
principles thereof. Subject to Section 10.1(b), and without limiting the rights of the parties to pursue in any appropriate jurisdiction their respective rights with respect to any judgment obtained in respect 

  

 24. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
hereof, the parties hereby irrevocably consent to the exclusive jurisdiction and venue of any United States court of competent jurisdiction located in the
State of Minnesota and/or the state courts located in Anoka County therein to adjudicate any legal action commenced in respect of this Agreement and waive any objections either may have at any time to such jurisdiction and venue. The parties agree
to the personal jurisdiction of such courts and agree that service of process may be made pursuant to notice sent in accordance with Section 10.5. 
 (b) Any dispute arising under this Agreement shall be referred first to the President of Supplier and the President of Medtronic Cardiac Rhythm Management or his or her designee (each a “Relationship
Manager”) within [*] business days after receipt of a notice from either Party specifying the nature of the dispute and referencing this Section. Each Relationship Manager shall make a good faith attempt to begin discussions regarding such
dispute in person or by telephone with the other Relationship Manger within [*] business days of a dispute being referred to him or her. The Relationship Managers shall meet as often as the Parties reasonably deem necessary in order to gather and
furnish to the other all information with respect to the matter in issue which the Parties believe to be appropriate and germane in connection with its resolution. The Relationship Managers shall discuss the problem and negotiate in good faith in an
effort to resolve the dispute without the necessity of any formal proceeding. Should the Relationship Managers fail to reach agreement within [*] days of the initiation of the dispute resolution process (or such longer period as such representatives
may agree in writing), then formal proceedings for the resolution of a dispute may be commenced in accordance with Exhibit C hereto. The results of such arbitration proceedings shall be binding upon the parties, and judgment may entered upon
the arbitration award in any court having jurisdiction thereof. Notwithstanding the foregoing, either party may seek interim injunctive relief from any court of competent jurisdiction. 
 10.2 Use of Name. No right, express or implied, is granted by this Agreement to either Party to use in any manner the name of the other or any
other trade name or trademark of the other. 
 10.3 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR 

  

 25. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 
INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. 
 10.4 Independent Parties. The Parties are not employees or legal representatives of the other Party for any purpose. Neither Party shall have the
authority to enter into any contracts in the name of or on behalf of the other Party. 
 10.5 Notice. All notices, including notices
of address change, required or permitted to be given under this Agreement shall be in writing and deemed to have been received (a) when received if hand delivered, (b) four (4) days after being sent by certified mail, postage prepaid,
(c) one (1) business day after being sent by overnight courier, or (d) when received if sent by confirmed facsimile, in each case sent to the address or facsimile number set forth below: (or any updated addresses communicated to the
other Party in writing) 
  

			
	 If to Supplier:
	  	 CardioMEMS, Inc.
 75 Fifth Street, N.W., Suite
440
 Atlanta, GA 30308
 Attention: CEO
 Facsimile: [*]

		
	 with a copy to:
	  	 Cooley Godward LLP
 Five Palo Alto Square
 3000 El Camino Real
 Palo Alto, CA 94306
 Attention: Frank F. Rahmani, Esq.
 Facsimile: (650)
849-7400

		
	 If to Purchaser:
	  	 Medtronic, Inc.
 World Headquarters
 710 Medtronic Parkway, N.E.
 Minneapolis, MN 55432-5604
 Attention: General Counsel
 FAX: [*]

		
	 with a copy to:
	  	 Medtronic, Inc.
 Cardiac Rhythm Management
 7000 Central Avenue, N.E.
 Minneapolis, MN 55432-3576
 Attention: Vice President and Senior Legal Counsel, CRM
 FAX:
[*]

  

 26. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 10.6 Severability. In the event any provision of this Agreement is held to be invalid or
unenforceable, the valid or enforceable portion thereof and the remaining provisions of this Agreement will remain in full force and effect. 
 10.7 Waiver. Any waiver (express or implied) by either Party of any breach of this Agreement shall not constitute a waiver of any other or subsequent breach. 
 10.8 Entire Agreement; Amendment. This Agreement and the exhibits attached hereto constitute the entire, final, complete and exclusive agreement
between the Parties and supersede all previous agreements or representations, written or oral, with respect to the subject matter of this Agreement, including without limitation the Confidential Disclosure Agreement between the Parties dated
April 27, 2005 and the Confidential Disclosure Agreement between the Parties dated June 24, 2002. All information to be kept confidential under such earlier confidentiality agreement as of the Effective Date shall be maintained as
Confidential Information by the receiving Party under the obligations set forth in Article 8 of this Agreement. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of each Party. 

10.9 Nonassignability; Binding on Successors. Any attempted assignment of the rights or delegation of the obligations under this Agreement
shall be void without the prior written consent of the nonassigning or nondelegating Party; provided, however, that either Party may assign its rights or delegate its obligations under this Agreement without such consent (i) to an Affiliate of
such Party or (ii) to its successor in interest in connection with any merger, consolidation, or sale of all or substantially all of the assets, or the sale or transfer of the business relating to the subject matter hereof, of such Party. This
Agreement shall be binding upon, and inure to the benefit of, the successors, executors, heirs, representatives, administrators and permitted assigns of the Parties hereto. 
  

 27. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 10.10 Excused Performance. 
 (a) If a Party is prevented from performing its obligations hereunder (other than the obligation to pay money that has come due pursuant to this
Agreement) solely as a result of a strike, riot, war, invasion, act of God, fire, explosion, flood, act of government agency or instrumentality, judicial action, or similar event or condition, in each case which is outside the reasonable control of
such party and which did not exist and was not reasonably foreseeable as of the date hereof (a “Force Majeure”), such Party’s performance hereunder will be temporarily excused as provided in this Section, only by the degree affected
and after such Party has taken (and so long as such Party continues to take) all reasonable action to avoid being so affected; provided, that such party delivers to the other party written notice promptly upon learning of such event or condition,
which notice shall include a detailed description of the event or condition and the anticipated effect on such Party’s ability to perform its obligations hereunder, as well as a reasonably detailed description of specific actions such Party
plans to take to resume full performance hereunder. 
 (b) Upon giving notice to the other Party, a Party affected by a Force Majeure
shall be excused from the performance of its obligations under this Agreement as described in Section 10.10(a), except for the obligation to pay any amounts due and owing hereunder, but only to the extent and only for the period (not to exceed
[*]) that its performance of such obligations is prevented by such Force Majeure. If Supplier is the Party affected by the Force Majeure and has not fully resumed performance by the end of such period, Purchaser shall be entitled to exercise the
Back-Up Manufacturing Right pursuant to Section 2.4(e) of the License Agreement. Nothing in this Section shall affect Purchaser’s right to cancel purchase orders as provided in Section 2.3 or Purchaser’s right to exercise the
Back-Up Manufacturing Right under Sections 2.4(a) or 2.4(b) of the License Agreement. 
 (c) During the period that the performance by
one of the Parties of its obligations under this Agreement has been suspended by reason of an event of Force Majeure, the other Party may likewise suspend the performance of all or part of its obligations hereunder (other than the obligation to pay
money that has come due pursuant to this Agreement) to the extent that such suspension is commercially reasonable. 
  

 28. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 10.11 Publicity. In the event either party proposes to issue any press release or public
announcement concerning any provisions of this Agreement or the transactions contemplated hereby, such party shall so advise the other party hereto, and the parties shall thereafter use their reasonable best efforts to cause a mutually agreeable
release or announcement to be issued. Neither party will publicly disclose or divulge any provisions of this Agreement or the transactions contemplated hereby without the other parties’ written consent, except as may be required by applicable
law (including applicable SEC rules and regulations) or stock exchange regulation; provided that, prior to disclosure of any provision of this Agreement to any governmental agency or stock exchange, the parties shall cooperate to seek confidential
treatment or other applicable limitations on the public availability of any information that either of the parties considers sensitive or confidential. 
 10.12 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which shall constitute together the same instrument. 
 IN WITNESS WHEREOF, the Parties hereto have duly executed this Supply Agreement as of the Effective
Date. 
  

									
	CARDIOMEMS, INC.	 		 	MEDTRONIC, INC.
					
	By:	 	/s/ David R. Stern	 		 	By:	 	/s/ Michael D. Ellwein

									
					
	Name:	 	David R. Stern	 		 	Name:	 	Michael D. Ellwein

									
					
	Title:	 	President & CEO	 		 	Title:	 	Vice President & Chief Development Officer

									
					
	Date:	 	11/15/05	 		 	Date:	 	  

  

 29. 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 EXHIBIT A 
 [*] SPECIFICATIONS 
 [*] 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 EXHIBIT B 
 QUALIFIED VENDORS 
 [*] 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 EXHIBIT C 
 ALTERNATIVE DISPUTE RESOLUTION 
 1.0 Arbitration. In the event the parties are unable
to resolve a dispute using the escalation procedure described in Section 10.1(b), the parties agree that any and all disputes, claims or controversies arising out of or relating to this Supply Agreement shall be resolved by binding arbitration
conducted as follows: 
 1.1 Notice. Notice of demand for binding arbitration shall be delivered to the other party in
accordance with the provisions of the Supply Agreement. In no event may a notice of demand of any kind be filed more than two years after the date the claim, dispute, controversy, or other matter in question arose, and if such demand is not timely
filed, the claim, dispute, controversy, or other matter in question referenced in the demand shall be deemed released, waived, barred, and unenforceable for all time, and barred as if by statute of limitations. 
 1.2 Binding Arbitration. Upon filing of a notice of demand for binding arbitration by either party, arbitration shall be commenced and conducted
as follows: 
 a. Arbitrator. All claims, disputes, controversies, and other matters (collectively “matters”) in question
shall be referred to and decided and settled by an arbitrator selected with assistance from the CPR Institute for Dispute Resolution (CPR). Selection of an arbitrator shall be made within [*] days after the date of the first notice of demand given
pursuant to Section 1.1 and within [*] days after any resignation, disability or other removal of such arbitrator. 
 b. Costs of
Arbitration. The cost of arbitration proceedings, including without limitation the arbitrator’s compensation and expenses, hearing room charges, court reporter transcript charges, etc., shall be borne by the parties equally or otherwise as
the arbitrator may determine. The arbitrator may award the party that prevails substantially in its pre-hearing position part or all of its reasonable attorneys’ fees and costs incurred in connection with the arbitration. The arbitrator is
specifically instructed to award attorneys’ fees for instances of abuse of the discovery process. 
 c. Location of Proceedings.
All arbitration proceedings shall be held in [*], if the proceeding is initiated by Supplier, or in [*], if the proceeding is initiated by Purchaser, at a location selected by the initiating party in the applicable city. 
 d. Pre-hearing Discovery. The parties shall have the right to conduct and enforce pre-hearing discovery in accordance with the then current Federal
Rules of Civil Procedure subject to these limitations: 
 (1) Each party may serve no more than [*] sets of interrogatories; 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 (2) Each party may depose the other party’s expert witnesses who will be called to testify at
the hearing, plus [*] fact witnesses without regard to whether they will be called to testify (each party will be entitled to a total of not more than [*] hours per each deposition of the other party’s witnesses); and 
 (3) Document discovery and other discovery shall: (i) be limited to matters that are directly relevant and material to the matters, and (ii) be
under the control of and enforceable by the arbitrator. 
 (4) Discovery disputes shall be decided by the arbitrator. The arbitrator is
empowered: 
 (i) To issue subpoenas to compel pre-hearing document or deposition discovery; 
 (ii) To enforce the discovery rights and obligations of the parties; 
 (iii) To truncate discovery proceedings; 
 (iv) To further limit the number of witnesses involved in the
proceeding; 
 (v) Otherwise to control the scheduling and conduct of the proceedings. 
 e. Conduct of Arbitration. 
 (1)
Pre-hearing Conference. Within [*] days after appointment, the arbitrator shall hold a pre-hearing conference to establish schedules for completion of discovery, for exchange of exhibit and witness lists, for arbitration briefs, for the
hearing, and to decide procedural matters and all other questions that may be presented. 
 (2) Hearing Procedures. The hearing shall
be conducted to preserve its privacy and to allow reasonable procedural due process. Rules of evidence need not be strictly followed, and the hearing shall be streamlined; 
 (i) Documents shall be self-authenticating, subject to valid objection by the opposing party; 

 Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 (ii) Expert reports, witness biographies, depositions, and affidavits may be utilized, subject to
the opponent’s right of a live cross-examination of the witness in person; 
 (iii) Charts, graphs, and summaries shall be utilized to
present voluminous data, provided (i) that the underlying data was made available to the opposing party [*] days prior to the hearing, and (ii) that the preparer of each chart, graph, or summary is available for explanation and live
cross-examination in person. 
 (iv) The hearing should be held on consecutive business days without interruption to the maximum extent
practicable. 
 (v) The arbitrator shall establish all other procedural rules for the conduct of the arbitration in accordance with the rules
of arbitration of the Center for Public Resources. 
 f. Governing Law. This arbitration provision shall be governed by, and all rights
and obligations specifically enforceable under and pursuant to, the Federal Arbitration Act (9 U.S.C. § 1, et seq.). 
 g.
Consolidation. No arbitration shall include, by consolidation, joinder, or in any other manner, any additional person not a party to this Agreement (other than Affiliates of any such party, which Affiliates may be included in the
arbitration), except by written consent of both parties containing a specific reference to this Agreement. 
 h. Award. The arbitrator
is empowered to render an award of general compensatory damages, but are not empowered to award equitable relief (including, without limitation, injunctive relief), exemplary or punitive damages, or any additional damage award in any patent dispute
for willful infringement, and each party agrees that it shall not seek such an award from the arbitrator. The award rendered by the arbitrator (1) shall be final; (2) shall not constitute a basis for collateral estoppel as to any issue;
and (3) shall not be subject to vacation or modification. 
 i. Confidentiality. The parties hereto will maintain the substance of
any proceedings hereunder in confidence and the arbitrator, prior to any proceedings hereunder, will sign an agreement whereby the arbitrator agrees to keep the substance of any proceedings hereunder in confidence. 
 j. Time Frame. To the fullest extent practicable pre-hearing discovery, pre-hearing conferences and hearing procedures shall be expedited and the
parties shall use their best reasonable efforts to conclude such alternate dispute resolution proceeding within [*] days to the event feasible and practicable under the circumstances. 

 EXHIBIT D 
 COMPETITORS OF MEDTRONIC 
 [*]Amended and Restated Investor Rights Agreement

 Exhibit 10.18 
 CARDIOMEMS, INC. 
 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 SEPTEMBER 18, 2006 

					
	SECTION 1.	  	    GENERAL.	  	1
			
	 1.1
	  	Amendment and Restatement of Prior Agreement.	  	1
			
	 1.2
	  	Definitions.	  	2
			
	SECTION 2.	  	    REGISTRATION; RESTRICTIONS ON TRANSFER.	  	4
			
	 2.1
	  	Restrictions on Transfer.	  	4
			
	 2.2
	  	Demand Registration.	  	5
			
	 2.3
	  	Piggyback Registrations.	  	7
			
	 2.4
	  	Form S-3 Registration.	  	8
			
	 2.5
	  	Expenses of Registration.	  	10
			
	 2.6
	  	Obligations of the Company.	  	10
			
	 2.7
	  	Termination of Registration Rights.	  	12
			
	 2.8
	  	Delay of Registration; Furnishing Information.	  	12
			
	 2.9
	  	Indemnification.	  	12
			
	 2.10
	  	Assignment of Registration Rights	  	15
			
	 2.11
	  	Amendment of Registration Rights.	  	15
			
	 2.12
	  	“Market Stand-Off” Agreement.	  	15
			
	 2.13
	  	Agreement to Furnish Information.	  	16
			
	 2.14
	  	Rule 144 Reporting.	  	16
			
	 2.15
	  	Limitations on Subsequent Registration Rights	  	17
			
	SECTION 3.	  	    COVENANTS OF THE COMPANY.	  	17
			
	 3.1
	  	Basic Financial Information and Reporting.	  	17
			
	 3.2
	  	Inspection Rights.	  	18
			
	 3.3
	  	Confidentiality of Records	  	18
			
	 3.4
	  	Meetings of the Board of Directors	  	19
			
	 3.5
	  	Board Committees	  	19
			
	 3.6
	  	Reservation of Common Stock.	  	19
			
	 3.7
	  	Stock Vesting.	  	19
			
	 3.8
	  	Voting Agreement	  	19
			
	 3.9
	  	Key Man Insurance.	  	20
			
	 3.10
	  	Proprietary Information and Inventions Agreement.	  	20
			
	 3.11
	  	Directed Shares	  	20
			
	 3.12
	  	Reimbursement	  	21
			
	 3.13
	  	Form D	  	21
			
	 3.14
	  	Taxes	  	21
			
	 3.15
	  	Visitation Rights	  	22

					
	 3.17
	  	Termination of Covenants.	  	23
			
	SECTION 4.	  	    RIGHTS OF FIRST REFUSAL.	  	23
			
	 4.1
	  	Subsequent Offerings.	  	23
			
	 4.2
	  	Exercise of Rights.	  	24
			
	 4.3
	  	Issuance of Equity Securities to Other Persons.	  	24
			
	 4.4
	  	Termination and Waiver of Rights of First Refusal.	  	24
			
	 4.5
	  	Transfer of Rights of First Refusal.	  	25
			
	 4.6
	  	Excluded Securities.	  	25
			
	SECTION 5.	  	    MISCELLANEOUS.	  	25
			
	 5.1
	  	Governing Law.	  	26
			
	 5.2
	  	Successors and Assigns.	  	26
			
	 5.3
	  	Entire Agreement.	  	26
			
	 5.4
	  	Severability.	  	26
			
	 5.5
	  	Amendment and Waiver.	  	26
			
	 5.6
	  	Delays or Omissions.	  	27
			
	 5.7
	  	Notices.	  	27
			
	 5.8
	  	Titles and Subtitles.	  	27
			
	 5.9
	  	Additional Investors.	  	27
			
	 5.10
	  	Counterparts.	  	27
			
	 5.11
	  	Aggregation of Stock	  	27
			
	 5.12
	  	Pronouns.	  	28

 CARDIOMEMS, INC. 
 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 THIS AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 18th day of September, 2006, by and among
CARDIOMEMS, INC., a Delaware corporation (the “Company”) and each of the persons and entities listed on EXHIBIT A hereto, referred to hereinafter as the
“Investors” and each individually as an “Investor.” 
 RECITALS 
 WHEREAS, certain of the Investors are purchasing shares of the Company’s Series D Preferred Stock (the
“Series D Stock”), pursuant to that certain Series D Stock Purchase Agreement (the “Purchase Agreement”) of even date herewith (the “Financing”); 
 WHEREAS, the obligations in the Purchase Agreement are conditioned upon the execution and delivery of this Agreement; 

WHEREAS, certain of the Investors (the “Prior Investors”) are holders of the Company’s Series A
Preferred Stock (the “Series A Stock”), the Company’s Series B Preferred Stock (the “Series B Stock”) and, as the case may be, Series C Preferred Stock (the “Series C Stock,” and together
with the Series A Stock, Series B Stock and Series D Stock, the “Preferred Stock”); 
 WHEREAS,
the Prior Investors and the Company are parties to an Amended and Restated Investor Rights Agreement dated November 18, 2005 (the “Prior Agreement”); 
 WHEREAS, the parties to the Prior Agreement desire to amend and restate the Prior Agreement and accept the rights and covenants
hereof in lieu of their rights and covenants under the Prior Agreement; and 
 WHEREAS, in connection with the
consummation of the Financing, the Company and the Investors have agreed to the registration rights, information rights, and other rights as set forth below. 
 NOW, THEREFORE, in consideration of these premises and for other good and valid consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows: 
 SECTION 1. GENERAL. 
 1.1 Amendment and Restatement of Prior Agreement. The Prior Agreement is hereby amended in its entirety and restated herein. Such amendment and restatement is effective upon the execution of this Agreement by
the Company and the holders of at least the respective majority of both the Registrable Securities and the Demand Registrable Securities (as both terms are defined herein) held by the Prior Investors outstanding as of the date of this Agreement.
Upon such execution, all provisions of, rights granted and covenants made in the Prior Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect, including, without limitation, all rights of
first refusal and any notice period associated therewith otherwise applicable to the transactions contemplated by the Purchase Agreement, and each of the Prior Investors hereby irrevocably waives, and releases the Company from, any and all claims
such Prior Investor has or may have against the Company arising out or as a result of (a) the Prior Agreement or (b) the amendment and restatement of the Prior Agreement as provided for under this Section 1.1. 
  

 1 

 1.2 Definitions. As used in this Agreement the following terms shall have the following respective
meanings: 
 (a) “Affiliated Party” means, with respect to a Holder or an Investor, as the case may be, any
person or entity which, directly or indirectly, controls, is controlled by or is under common control with such Holder or Investor, as the case may be, including, without limitation, any general partner, member, officer or director of such Holder or
Investor, as the case may be, and any venture capital fund now or hereafter existing which is controlled by one or more general partners of, or shares the same management company as, such Holder or Investor, as the case may be and, with respect to
Guidant Investment Corporation, shall include the Guidant Foundation. 
 (b) “Demand Holder” means any person
owning of record Demand Registrable Securities that have not been sold to the public or any assignee of record of such Demand Registrable Securities in accordance with Section 2.10 hereof. 
 (c) “Demand Registrable Securities” means (a) Common Stock of the Company issuable or issued upon conversion of the
Series B Stock, Series C Stock or Series D Stock, (b) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right, option or other security which is issued as) a dividend or other distribution
with respect to, or in exchange for or in replacement of, such above-described securities, and (c) any other shares of Common Stock of the Company acquired by a Series D Investor (or any Affiliated Party of such Series D Investor) after the
date hereof pursuant to exercise of such Series D Investor’s rights under the Purchase Agreement or any Related Agreement (as defined in the Purchase Agreement). Notwithstanding the foregoing, Demand Registrable Securities shall not include any
securities (i) sold by a person to the public either pursuant to a registration statement under the Securities Act or Rule 144 promulgated thereunder or (ii) sold in a private transaction in which the transferor’s rights under
Section 2 of this Agreement are not assigned. 
 (d) “Exchange Act” means the Securities Exchange Act of
1934, as amended. 
 (e) “Form S-3” means such form under the Securities Act as in effect on the date hereof
or any successor or similar registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

(f) “Holder” means any person owning of record Registrable Securities that have not been sold to the public or any
assignee of record of such Registrable Securities in accordance with Section 2.10 hereof. For purposes of this Agreement, the term Holders is inclusive of Demand Holders, and the provisions applicable only to Demand Holders shall so state.

 (g) “Initial Offering” means the Company’s first firm commitment underwritten public offering of its
Common Stock registered under the Securities Act. 
 (h) “Register,” “registered,” and
“registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or
document. 
  

 2. 

 (i) “Registrable Securities” means (a) Common Stock of the Company
issuable or issued upon conversion of the Shares, (b) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right, option or other security which is issued as) a dividend or other distribution
with respect to, or in exchange for or in replacement of, such above-described securities, and (c) any other shares of Common Stock of the Company acquired by an Investor (or any Affiliated Party of such Investor) after the date hereof pursuant
to exercise of such an Investor’s rights under the Purchase Agreement or any Related Agreement (as defined in the Purchase Agreement). Notwithstanding the foregoing, Registrable Securities shall not include any securities (i) sold by a
person to the public either pursuant to a registration statement under the Securities Act or Rule 144 or (ii) sold in a private transaction in which the transferor’s rights under Section 2 of this Agreement are not assigned. For
purposes of this Agreement, the term Registrable Securities is inclusive of Demand Registrable Securities, and provisions applicable only to Demand Registrable Securities shall so state. 
 (j) “Registrable Securities then outstanding” shall be the number of shares of the Company’s Common Stock that are
Registrable Securities and either (a) are then issued and outstanding or (b) are issuable pursuant to then exercisable or convertible securities. 
 (k) “Registration Expenses” shall mean all expenses incurred by the Company in complying with Sections 2.2, 2.3 and 2.4 hereof, including, without limitation, all registration and
filing fees, printing expenses, fees and disbursements of counsel for the Company, reasonable fees and disbursements not to exceed thirty-five thousand dollars ($35,000) of a single special counsel for the Holders determined by a majority of the
Holders participating in the offering described in Sections 2.2, 2.3 or 2.4, as the case may be, blue sky fees and expenses and the expense of any special audits incident to or required by any such registration (but excluding the compensation of
regular employees of the Company which shall be paid in any event by the Company). 
 (l) “SEC” or
“Commission” means the Securities and Exchange Commission. 
 (m) “Securities Act”
shall mean the Securities Act of 1933, as amended. 
 (n) “Selling Expenses” shall mean all
underwriting discounts and selling commissions applicable to the sale. 
 (o) “Series D Investor” means those
Investors purchasing shares of Series D Stock on the date hereof pursuant to the Purchase Agreement. 
 (p) “Shares”
shall mean the Company’s Series A Stock, Series B Stock, Series C Stock and Series D Stock held from time to time by the Investors listed on EXHIBIT A hereto and their permitted assigns. 
 (q) “Special Registration Statement” shall mean (i) a registration statement relating to any employee benefit plan or
(ii) with respect to any corporate reorganization or transaction under Rule 145 of the Securities Act, any registration statements related to the issuance or resale of securities issued in such a transaction or (iii) a registration
related to stock issued upon conversion of debt securities. 
  

 3. 

 SECTION 2. REGISTRATION; RESTRICTIONS ON TRANSFER. 
 2.1 Restrictions on Transfer. 
 (a)
Each Holder agrees not to make any disposition of all or any portion of the Shares or Registrable Securities unless and until: 
 (i)
there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 
 (ii) (A) The transferee has agreed in writing to be bound by the terms of this Agreement, (B) such Holder shall have notified the
Company of the proposed disposition and shall have furnished the Company with a reasonably detailed statement of the circumstances surrounding the proposed disposition, and (C) if reasonably requested by the Company, such Holder shall have
furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares under the Securities Act. It is agreed that the Company will not require opinions of counsel
for transactions made pursuant to Rule 144, except in unusual circumstances. After its Initial Offering, the Company will not require the transferee pursuant to Rule 144 to be bound by the terms of this Agreement. 
 (b) Notwithstanding the provisions of subsection (a) above, no such restriction shall apply to a transfer by a Holder that is (A) a
partnership transferring to its partners, or former partners or to any other partnership that is an Affiliated Party of such Holder or to partners or former partners of any such other partnership, (B) an entity transferring to a wholly-owned
subsidiary or a parent entity that owns all of the capital stock of the Holder or to any other entity that is an Affiliated Party of such Holder, (C) a limited liability company transferring to its members, or former members or to any other
limited liability company that is an Affiliated Party of such Holder or to members or former members of any such limited liability company, (D) an individual transferring to the Holder’s family member or trust for the benefit of such
Holder and/or such Holder’s family members, (E) Arcapita Ventures I Limited transferring to its non-individual shareholders or any other entity that is an Affiliated Party of such Holder, or (F) Guidant Investment Corporation
transferring to Guidant Foundation; provided that in each case the transferee will agree in writing to be subject to the terms of this Agreement to the same extent as if he were an original Holder hereunder. 
 (c) Each certificate representing Shares or Registrable Securities shall be stamped or otherwise imprinted with legends substantially similar to
the following (in addition to any legend required under applicable state securities laws): 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN
OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 
  

 4. 

 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT
TO THE TERMS AND CONDITIONS OF A CERTAIN INVESTOR RIGHTS AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 
 (d) The Company shall be obligated to reissue promptly unlegended certificates at the request of any Holder thereof if the Company has completed
its Initial Offering and the Holder shall have obtained an opinion of counsel (which counsel may be counsel to the Company) reasonably acceptable to the Company to the effect that the securities proposed to be disposed of may lawfully be so disposed
of without registration, qualification and legend. 
 (e) Any legend endorsed on an instrument pursuant to applicable state securities
laws and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company of an order of the appropriate blue sky authority authorizing such removal. 
 2.2 Demand Registration. 
 (a)
Subject to the conditions of this Section 2.2, if the Company shall receive a written request from the Demand Holders of a majority of the Demand Registrable Securities then outstanding (the “Demand Initiating Holders”)
that the Company file a registration statement under the Securities Act covering the registration of at least a majority of the Demand Registrable Securities then outstanding, then the Company shall, within fifteen (15) days of the
receipt thereof, give written notice of such request to all Demand Holders, and subject to the limitations of this Section 2.2, effect, as expeditiously as reasonably possible, the registration under the Securities Act of all Demand Registrable
Securities that all Demand Holders request in writing to the Company within twenty (20) business days after delivery of such notice, to be registered. 
 (b) If the Demand Initiating Holders intend to distribute the Demand Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made
pursuant to this Section 2.2 and the Company shall include such information in the written notice referred to in Section 2.2(a). In such event, the right of any Demand Holder to include its Demand Registrable Securities in such
registration shall be conditioned upon such Demand Holder’s participation in such underwriting and the inclusion of such Demand Holder’s Demand Registrable Securities in the underwriting to the extent provided herein. All Demand Holders
proposing to distribute their securities through such underwriting shall enter into, and perform their respective obligations under, an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by a
majority in interest of the Demand Initiating Holders (which underwriter or underwriters shall be reasonably acceptable to the Company); provided that such underwriting agreement shall not provide for indemnification or contribution obligations on
the part of the Demand Holders materially greater than the obligations of the Holders pursuant to Section 2.9. If any Demand Holder who has requested inclusion of its Demand Registrable Securities in such registration as provided above
disapproves of the terms of the underwriting, such person may elect, by written notice to the Company, to withdraw its Demand Registrable Securities from such Registration Statement and underwriting. Notwithstanding any other provision of this
Section 2.2, if the underwriter advises the Company that marketing factors require a limitation of the number of securities to be underwritten (including Demand Registrable Securities) then the Company shall so advise all Demand Holders of
Demand Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be allocated to the Demand Holders of such Demand Registrable 

  

 5. 

 
Securities on a pro rata basis based on the number of Demand Registrable Securities held by all such Demand Holders (including the Demand Initiating
Holders). Any Demand Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. 
 (c)
The Company shall not be required to effect a registration pursuant to this Section 2.2: 
 (i) prior to the earlier of
(A) the fifth anniversary of the date of this Agreement or (B) the expiration of the restrictions on transfer set forth in Section 2.12 following the Initial Offering; 
 (ii) after the Company has effected two (2) registrations pursuant to this Section 2.2, and such registrations have been declared or
ordered effective; provided, however, that a registration statement shall not be counted if, as a result of an exercise of the underwriter’s cut-back provisions, less than 50% of the total number of Demand Registrable Shares that Demand
Holders have requested to be included in such registration statement are so included; 
 (iii) if the Company shall furnish to Demand
Holders requesting a registration statement pursuant to this Section 2.2, a certificate signed by the Chairman of the Board of Directors stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously
detrimental to the Company and its stockholders for such registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than ninety (90) days after receipt of
the request of the Initiating Holders; provided that such right to delay a request shall be exercised by the Company not more than once in any twelve (12) month period; 
 (iv) If the Demand Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3
pursuant to a request made pursuant to Section 2.4 hereof; or 
 (v) in any particular jurisdiction in which the Company would
be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance. 
 2.3 Piggyback Registrations. The Company shall notify all Holders of Registrable Securities in writing at least twenty (20) business days prior to the filing of any registration statement under the
Securities Act for purposes of a public offering of securities of the Company (including, but not limited to, registration statements relating to secondary offerings of securities of the Company, but excluding Special Registration Statements) and
will afford each such Holder an opportunity to include in such registration statement all or part of such Registrable Securities held by such Holder. Each Holder desiring to include in any such registration statement all or any part of the
Registrable Securities held by it shall, within fifteen (15) business days after the above-described notice from the Company, so notify the Company in writing. Such notice shall state the intended method of disposition of the Registrable
Securities by such Holder. If a Holder decides not to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable
Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. 
 (a) Underwriting. If the registration statement under which the Company gives notice under this Section 2.3 is for an underwritten offering,
the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder to include Registrable Securities in a 

  

 6. 

 
registration pursuant to this Section 2.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such
Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their Registrable Securities through such underwriting shall enter into, and perform their respective obligations under, an
underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company; provided that such underwriting agreement shall not provide for indemnification or contribution obligations on the
part of the Holders materially greater than the obligations of the Holders pursuant to Section 2.9. Notwithstanding any other provision of this Agreement, if the underwriter determines in good faith that marketing factors require a limitation
of the number of shares to be underwritten, the number of shares that may be included in the underwriting shall be allocated, first, to the Company; second, to the Holders on a pro rata basis based on the total number of Registrable
Securities held by the Holders; and third, to any stockholder of the Company (other than a Holder) on a pro rata basis; provided, however, that with respect to a registration effected pursuant to Section 2.2 hereof, no Registrable
Securities requested to be included in the registration and underwriting by any person other than Demand Holders shall be included in such registration and underwriting unless and until all Registrable Securities held by Demand Holders and requested
to be so registered pursuant to Section 2.2 hereof, have been included in such registration; and provided, further, that no such reduction shall (i) reduce the securities being offered by the Company for its own account to be
included in the registration and underwriting, or (ii) reduce the amount of securities of the selling Holders included in the registration below twenty-five percent (25%) (or, with respect to a registration effected pursuant to
Section 2.2 hereof, fifty percent (50%)) of the total amount of securities included in such registration, unless such offering is the Initial Offering and such registration does not include shares of any other selling stockholders, in
which event any or all of the Registrable Securities of the Holders may be excluded in accordance with the immediately preceding clause. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by
written notice to the Company and the underwriter, delivered at least ten (10) business days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded
and withdrawn from the registration. For any Holder which is a partnership, limited liability company or corporation, the partners, retired partners, members, retired members, Affiliated Parties and stockholders of such Holder, or the estates and
family members of any such partners, members, retired members and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “Holder,” and any pro rata reduction with respect to
such “Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “Holder,” as defined in this sentence. 
 (b) Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this
Section 2.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. The Registration Expenses of such withdrawn registration shall be borne by the Company in accordance
with Section 2.5 hereof. 
 2.4 Form S-3 Registration. In case the Company shall receive from any Holder or Holders of
Registrable Securities a written request or requests that the Company effect a registration on Form S-3 (or any successor to Form S-3) or any similar short-form registration statement and any related qualification or compliance with
respect to all or a part of the Registrable Securities owned by such Holder or Holders (the “Initiating Holders”), the Company will: 
 (a) promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders of Registrable Securities; and 
  

 7. 

 (b) as soon as practicable, effect such registration and all such qualifications and compliances
as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Initiating Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable
Securities of any other Holder or Holders joining in such request as are specified in a written request given within twenty (20) business days after receipt of such written notice from the Company; provided, however, that the Company
shall not be obligated to effect any such registration, qualification or compliance pursuant to this Section 2.4: 
 (i) if
Form S-3 (or any successor to Form S-3) is not available for such offering by the Holders; 
 (ii) if the Holders, together with
the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than one million five hundred
thousand dollars ($1,500,000); 
 (iii) if the Company shall furnish to the Holders a certificate signed by the Chairman of the Board
of Directors of the Company stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such Form S-3 registration to be effected at such time, in
which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more than ninety (90) days after receipt of the request of the Holder or Holders under this Section 2.4;
provided, that such right to delay a request shall be exercised by the Company not more than once in any twelve (12) month period; 
 (iv) if the Company has, within the twelve (12) month period immediately preceding the date of such request, already effected three (3) registrations on Form S-3 for the Holders pursuant to this Section 2.4, or

 (v) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general
consent to service of process in effecting such registration, qualification or compliance. 
 (c) If the Initiating Holders intend to
distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.4 and the Company shall include such information in the
written notice referred to in Section 2.4(a). In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of
such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities
through such underwriting shall enter into, and perform their respective obligations under, an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by a majority in interest of the Initiating
Holders (which underwriter or underwriters shall be reasonably acceptable to the Company); provided that such underwriting agreement shall not provide for indemnification or contribution obligations on the part of the Holders materially greater than
the obligations of the Holders pursuant to Section 2.9. If any Holder who has requested inclusion of its Registrable Securities in such registration as provided above disapproves of the terms of the underwriting, such person may elect, by
written notice to the Company, to withdraw its Registrable Securities from such Registration Statement and underwriting. Notwithstanding any other provision of this Section 2.4, if the underwriter advises the Company that marketing factors
require a limitation of the number of securities to be underwritten (including Registrable Securities) then the Company shall so advise all Holders of Registrable Securities which would otherwise be underwritten 

  

 8. 

 
pursuant hereto, and the number of shares that may be included in the underwriting shall be allocated to the Holders of such Registrable Securities on a pro
rata basis based on the number of Registrable Securities held by all such Holders (including the Initiating Holders). Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. 
 (d) Subject to the foregoing, the Company shall file a Form S-3 registration statement covering the Registrable Securities and other
securities so requested to be registered as soon as practicable after receipt of the requests of the Holders. Registrations effected pursuant to this Section 2.4 shall not be counted as demands for registration or registrations effected
pursuant to Section 2.2. 
 2.5 Expenses of Registration. Except as specifically provided herein, all Registration Expenses
incurred in connection with any registration, qualification or compliance pursuant to Section 2.2 or any registration under Section 2.3 or Section 2.4 herein shall be borne by the Company. All Selling Expenses incurred in connection
with any registrations hereunder, shall be borne by the holders of the securities so registered pro rata on the basis of the number of shares so registered. The Company shall not, however, be required to pay for expenses of any registration
proceeding begun pursuant to Section 2.2 or 2.4, the request of which has been subsequently withdrawn by the Demand Initiating Holders or the Initiating Holders, as the case may be, unless (a) the withdrawal is based upon material adverse
information concerning the Company of which the Demand Initiating Holders or the Initiating Holders were not aware at the time of such request or (b) the Holders of a majority of Registrable Securities agree to forfeit their right to one
requested registration pursuant to Section 2.4 or the Demand Holders of a majority of Demand Registrable Securities agree to forfeit their right to one requested registration pursuant to Section 2.2, as applicable, in which event such
right shall be forfeited by all Holders or Demand Holders, as applicable. If the Demand Holders or the Holders are required to pay the Registration Expenses, such expenses shall be borne by the holders of securities (including Demand Registrable
Securities or Registrable Securities) requesting such registration in proportion to the number of shares for which registration was requested. If the Company is required to pay the Registration Expenses of a withdrawn offering pursuant to
clause (a) above, then the Demand Holders or Holders shall not forfeit their rights pursuant to Section 2.2 or Section 2.4 to a registration. 
 2.6 Obligations of the Company. Whenever required to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use all reasonable efforts to cause such
registration statement to become effective, and keep such registration statement effective for one hundred and eighty (180) days (or one year in the case of a registration on Form S-3 (or any successor to Form S-3) pursuant to Section 2.4)
or, if earlier, until the Holder or Holders have completed the distribution related thereto; provided, however, that at any time, upon written notice to the participating Holders and for a period not to exceed ninety (90) days thereafter (the
“Suspension Period”), the Company may delay the filing or effectiveness of any registration statement or suspend the use or effectiveness of any registration statement (and the participating Holders hereby agree not to offer or sell
any Registrable Securities pursuant to such registration statement during the Suspension Period) if the Company reasonably believes that the Company may, in the absence of such delay or suspension hereunder, be required under state or federal
securities laws to disclose any corporate development the disclosure of which could reasonably be expected to have a material adverse effect upon the Company. In the event that the Company shall exercise its right to delay or suspend the filing or
effectiveness of a registration hereunder, the applicable time period during which the registration statement is to remain effective shall be extended by a period of time equal to the duration of the Suspension Period. The Company may extend the
Suspension Period for an additional consecutive sixty (60) days with the consent of the holders of a majority of the Registrable Securities registered under the applicable registration statement, which consent shall not be unreasonably 

  

 9. 

 
withheld. If so directed by the Company, all Holders registering shares under such registration statement shall use all reasonable efforts to deliver to the
Company (at the Company’s expense) all copies, other than permanent file copies then in such Holders’ possession, of the prospectus relating to such Registrable Securities current at the time of receipt of such notice. Any registration
statement prepared pursuant hereto (and each amendment or supplement thereto) shall be made available to the Holders and/or their counsel. 
 (b) Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the
Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth in subsection (a) above. 
 (c) Furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably
request in order to facilitate the disposition of Registrable Securities owned by them. 
 (d) Use all reasonable efforts to register
and qualify the securities and, if applicable, the re-sale by the Holders of the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders;
provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 
 (e) Cause all such Registrable Securities to be listed on each securities exchange or automated quotation system on which similar securities
issued by the Company are then listed. 
 (f) Provide a transfer agent and registrar for all such Registrable Securities not later
than the effective date of such registration statement. 
 (g) Make available for inspection by the Holders, any managing underwriter
participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the Holders, such Company records, documents and properties as are reasonably
necessary to, and requested by, any such Holder, underwriter, attorney, accountant or agent in connection with such registration statement. 
 (h) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter(s) of such offering. Each Holder participating
in such underwriting shall also enter into and perform its obligations under such an underwriting agreement. 
 (i) Notify each Holder
of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such
registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances
then existing. The Company will use all reasonable efforts to promptly amend or supplement such prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 
  

 10. 

 (j) Use all reasonable efforts to furnish, on the date that such Registrable Securities are
delivered to the underwriters for sale, if such securities are being sold through underwriters, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is
customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii) a letter, dated as of such date, from the independent certified public accountants of the Company, in form and substance as is
customarily given by independent certified public accountants to underwriters in an underwritten public offering addressed to the underwriters. 
 2.7 Termination of Registration Rights. All registration rights granted under this Section 2 shall terminate and be of no further force and effect five (5) years after the date of the Company’s Initial Offering.

 2.8 Delay of Registration; Furnishing Information. 
 (a) No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or
implementation of this Section 2. 
 (b) It shall be a condition precedent to the obligations of the Company to take any action
pursuant to Section 2.2, 2.3 or 2.4 that the selling Holders shall furnish to the Company such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities as shall be
required to effect the registration of their Registrable Securities. 
 2.9 Indemnification. In the event any Registrable Securities
are included in a registration statement under Sections 2.2, 2.3 or 2.4: 
 (a) To the extent permitted by law, the Company will
indemnify and hold harmless each Holder, the partners, members, officers and directors of each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the
meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a “Company Violation”) by the Company: (i) any untrue
statement or alleged untrue statement of a material fact contained in such registration statement or incorporated by reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements
thereto, or (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the
Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection with the offering covered by such registration statement; and the
Company will reimburse each such Holder, partner, member, officer, director, underwriter or controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage,
liability or action; provided however, that the indemnity agreement contained in this Section 2.9(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected
without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a
Company Violation which occurs in reliance upon and in conformity with written information furnished to the Company expressly for use in connection with such registration by such Holder, partner, member, officer, director, underwriter or controlling
person of such Holder. 
  

 11. 

 (b) To the extent permitted by law, each Holder severally and not jointly will, if Registrable
Securities held by such Holder are included in the securities as to which such registration qualifications or compliance is being effected, indemnify and hold harmless the Company, each of its directors, its officers and each person, if any, who
controls the Company within the meaning of the Securities Act, any underwriter and any other Holder selling securities under such registration statement or any of such other Holder’s partners, members, directors or officers or any person who
controls such Holder, against any losses, claims, damages or liabilities (joint or several) to which the Company or any such director, officer, controlling person, underwriter or other such Holder, or partner, member, director, officer or
controlling person of such other Holder may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based
upon any of the following statements: (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated by reference therein, including any preliminary prospectus or final
prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or
(iii) any violation or alleged violation by the Company of the Securities Act (collectively, a “Holder Violation”), in each case to the extent (and only to the extent) that such Holder Violation occurs in reliance upon and in
conformity with written information furnished by such Holder under an instrument duly executed by such Holder and stated to be specifically for use in connection with such registration; and each such Holder will reimburse any legal or other expenses
reasonably incurred by the Company or any such director, officer, controlling person, underwriter or other Holder, or partner, member, officer, director or controlling person of such other Holder in connection with investigating or defending any
such loss, claim, damage, liability or action if it is judicially determined that there was such a Holder Violation; provided, however, that the indemnity agreement contained in this Section 2.9(b) shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided further, that in no event shall any indemnity under
this Section 2.9 exceed the net proceeds from the offering received by such Holder. 
 (c) Promptly after receipt by an
indemnified party under this Section 2.9 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2.9, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other
indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses to
be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party
represented by such counsel in such proceeding. The indemnifying party shall also be responsible for the expenses of such defense if the indemnifying party does not elect to assume such defense. The failure to deliver written notice to the
indemnifying party within a reasonable time of the commencement of any such action, if materially prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this
Section 2.9, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.9. 
  

 12. 

 (d) If the indemnification provided for in this Section 2.9 is held by a court of competent
jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent permitted by
applicable law contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and
of the indemnified party on the other in connection with the Company Violation(s) or Holder Violation(s) that resulted in such loss, claim, damage or liability, as well as any other relevant equitable considerations. The relative fault of the
indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided, that in no event
shall any contribution by a Holder hereunder exceed the net proceeds from the offering received by such Holder. 
 (e) The obligations
of the Company and Holders under this Section 2.9 shall survive completion of any offering of Registrable Securities in a registration statement and the termination of this Agreement. No indemnifying party, in the defense of any such claim or
litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified
party of a release from all liability in respect to such claim or litigation. 
 2.10 Assignment of Registration Rights. The rights to
cause the Company to register Registrable Securities pursuant to this Section 2 may be assigned by a Holder to a transferee or assignee of Registrable Securities (for so long as such shares remain Registrable Securities) that (a) is a
subsidiary, parent, general partner, limited partner, retired partner, member or retired member, of such Holder, (b) is a Holder’s family member or trust for the benefit of an individual Holder and/or such Holder’s family members,
(c) acquires at least one hundred fifty thousand (150,000) shares of Registrable Securities (as adjusted for stock splits and combinations) or a lesser number representing all of the shares of Registrable Securities held by the
transferring Holder, (d) is an Affiliated Party of such Holder or a partner or former partner of such Affiliated Entity that is or was a partnership or a member or former member of such Affiliated Entity that is or was a limited liability
company, (e) is Arcapita Ventures I Limited transferring to its non-individual shareholders or any other entity that is an Affiliated Party of such Holder, or (f) in the case of Guidant Investment Corporation, is Guidant Foundation;
provided, however, (i) the transferor shall, within ten (10) days after such transfer, furnish to the Company written notice of the name and address of such transferee or assignee and the securities with respect to which such
registration rights are being assigned and (ii) such transferee shall agree to be subject to all restrictions set forth in this Agreement. 
 2.11 Amendment of Registration Rights. Any provision of this Section 2 may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only with
the written consent of the Company and the Holders of a majority of the Registrable Securities then outstanding. Any amendment or waiver effected in accordance with this Section 2.11 shall be binding upon each Holder and the Company. By
acceptance of any benefits under this Section 2, Holders of Registrable Securities hereby agree to be bound by the provisions hereunder. Notwithstanding the foregoing, (i) any amendment or waiver of the provisions of Section 2.2
hereof shall require the written consent of the Company and the Demand Holders of a majority of the Demand Registrable Securities then outstanding, and any amendment or waiver effected in accordance with this sentence shall be binding upon each
Demand Holder and the Company; and (ii) if any amendment or waiver adversely affects the rights and/or obligations of any party under this Agreement in a manner materially different from the manner in which it affects the rights and/or
obligations of the other parties, such amendment, modification or waiver shall also require the written consent of such adversely affected party. 
  

 13. 

 2.12 “Market Stand-Off” Agreement. Each Holder hereby agrees that such Holder shall not
sell, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Common Stock (or other securities) of the Company held by such Holder (other
than those included in the registration) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed one hundred eighty (180) days following the effective date of a
registration statement of the Company filed under the Securities Act (or such longer period, not to exceed eighteen days after the expiration of the one hundred eighty (180) day period, as the underwriters or the Company shall request in order
to facilitate compliance with NASD Rule 2711); provided that: 
 (a) such agreement shall apply only to the Company’s
Initial Offering; and 
 (b) all officers and directors of the Company enter into similar agreements. 
 The Company agrees to use all reasonable efforts to ensure that the “lock-up” obligation of the Holders under this Section 2.12, and any
agreement entered into by the Holders as a result of their obligations under this Section 2.12, shall provide that all Holders will participate on a pro-rata basis in any early release of portions of the securities of any stockholder subject to
such “lock-up” obligations. 
 2.13 Agreement to Furnish Information. Each Holder agrees to execute and deliver such other
agreements as may be reasonably requested by the Company or the underwriter that are consistent with the Holder’s obligations under Section 2.12 or that are necessary to give further effect thereto. In addition, if requested by the Company
or the representative of the underwriters of Common Stock (or other securities) of the Company, each Holder shall provide, within ten (10) days of such request, such information as may be required by the Company or such representative in
connection with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The obligations described in Section 2.12 and this Section 2.13 shall not apply to
a Special Registration Statement. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of said one hundred eighty (180) day period.
Each Holder agrees that any transferee of any shares of Registrable Securities shall be bound by Sections 2.12 and 2.13. The underwriters of the Company’s stock are intended third party beneficiaries of Section 2.12 and 2.13 and shall
have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 
 2.14 Rule 144 Reporting.
With a view to making available to the Holders the benefits of certain rules and regulations of the SEC which may permit the sale of the Registrable Securities to the public without registration, the Company agrees to use its best efforts to:

 (a) Make and keep public information available, as those terms are understood and defined in SEC Rule 144 or any similar or
analogous rule promulgated under the Securities Act, at all times after the earlier of (i) the effective date of the first registration filed by the Company for an offering of its securities to the general public, (ii) the registration by
the Company of a class of securities under Section 12 of the Exchange Act, or (iii) the issuance by the Company of an offering circular pursuant to Regulation A under the Securities Act; 
 (b) File with the SEC, in a timely manner, all reports and other documents required of the Company under the Securities Act and the Exchange Act;
and 
  

 14. 

 (c) So long as a Holder owns any Registrable Securities, furnish to such Holder forthwith upon
request: a written statement by the Company as to its compliance with the reporting requirements of said Rule 144 of the Securities Act, and of the Exchange Act (at any time after it has become subject to such reporting requirements); a copy of the
most recent annual or quarterly report of the Company filed with the SEC; and such other reports and documents as a Holder may reasonably request in connection with availing itself of any rule or regulation of the SEC allowing it to sell any such
securities without registration. 
 2.15 Limitations on Subsequent Registration Rights. The Company shall not, without the prior
written consent of Demand Holders holding at least fifty-five percent (55%) of the Demand Registrable Securities then held by all Demand Holders, enter into any agreement (other than this Agreement) with any holder or prospective holder of any
securities of the Company which grant such holder or prospective holder rights to include securities of the Company in any registration statement other than a Special Registration Statement. 
 SECTION 3. COVENANTS OF THE COMPANY. 
 3.1 Basic Financial Information
and Reporting. 
 (a) The Company will maintain true books and records of account in which full and correct entries will be made of
all its business transactions pursuant to a system of accounting established and administered in accordance with generally accepted accounting principles consistently applied, and will set aside on its books all such proper accruals and reserves as
shall be required under generally accepted accounting principles consistently applied. 
 (b) The Company will furnish each Investor,
as soon as practicable after the end of each fiscal year of the Company, and in any event within one-hundred eighty (180) days thereafter, an audited consolidated balance sheet of the Company, as at the end of such fiscal year, and an audited
consolidated statement of income and a statement of cash flows of the Company, for such year, all prepared in accordance with generally accepted accounting principles consistently applied (except as noted therein). Such financial statements shall be
accompanied by a report and opinion thereon by nationally recognized independent public accountants selected by the Company’s Board of Directors. 
 (c) So long as an Investor (together with its Affiliated Parties) shall own not less than three hundred thousand (300,000) shares of Registrable Securities (as adjusted for stock splits and combinations)
(a “Major Investor”), the Company will furnish such Major Investor: (i) at least thirty (30) days prior to the beginning of each fiscal year an annual budget and operating plans for such fiscal year (and as soon as
available, any subsequent written revisions thereto); and (ii) as soon as practicable after the end of each month, and in any event within thirty (30) days thereafter, a consolidated balance sheet of the Company as of the end of each such
month, and a consolidated statement of income and a statement of cash flows of the Company for such month and for the current fiscal year to date, prepared in accordance with generally accepted accounting principles consistently applied (except as
noted thereon), with the exception that no notes need be attached to such statements and year-end audit adjustments may not have been made. 
 3.2 Inspection Rights. Each Major Investor shall have the right to visit and inspect any of the properties of the Company or any of its subsidiaries, and to discuss the affairs, finances and accounts of the Company or any of its
subsidiaries with its officers, and to review such information as is reasonably requested all at such reasonable times and as often as may be reasonably requested; provided, however, that the Company shall not be obligated under this
Section 3.2 to provide such information to a 

  

 15. 

 
Major Investor to the extent the Company’s Board of Directors determines in good faith that withholding such information is necessary to preserve the
attorney-client privilege or to prevent a conflict of interest on the part of such Major Investor. 
 3.3 Confidentiality of Records.

 (a) Each Investor agrees not to use Confidential Information (as hereinafter defined) of the Company for its own use or for any
purpose except to evaluate and enforce its equity investment in the Company; provided, that Medtronic, Inc. (“Medtronic”) shall be permitted to use Confidential Information of the Company relating to the License and Development
Agreement or Supply Agreement as permitted under those agreements. Except as permitted under subsection (b) below, each Investor agrees to use all reasonable efforts not to disclose such Confidential Information to any third parties. Each
Investor shall undertake to treat such Confidential Information in a manner consistent with the treatment of its own information of such proprietary nature and agrees that it shall protect the confidentiality of and use all reasonable efforts to
prevent disclosure of the Confidential Information to prevent it from falling into the public domain or the possession of unauthorized persons. Each transferee of any Investor who receives Confidential Information shall agree to be bound by such
provisions. For purposes of this Section, “Confidential Information” means any information, trade secrets, data, or know-how, including, but not limited to, the Company’s patent applications, test or clinical data, licenses,
research, products, services, development, inventions, consultants’ or advisors’ identities, samples, processes, designs, engineering, marketing, finances, or business partners disclosed by the Company either directly or indirectly in
writing, orally or by drawings or inspection of samples. 
 (b) Confidential Information does not include information, technical data
or know-how which (i) is in the Investor’s possession at the time of disclosure as shown by Investor’s files and records immediately prior to the time of disclosure; (ii) before or after it has been disclosed to the Investor, it
is part of the public knowledge or literature, not as a result of any action or inaction of the Investor; (iii) is approved for release by written authorization of Company; or (iv) is rightfully disclosed to Investor by a third party
without restriction. The provisions of this Section 3.3 shall not apply (i) to the extent that an Investor is required to disclose Confidential Information pursuant to any law, statute, rule or regulation or any order of any court or
jurisdiction process or pursuant to any direction, request or requirement (whether or not having the force of law but if not having the force of law being of a type with which institutional investors in the relevant jurisdiction are accustomed to
comply) of any self-regulating organization or any governmental, fiscal, monetary or other authority; (ii) to the disclosure of Confidential Information to an Investor’s employees, counsel, accountants or other professional advisors
(“Investor Advisors”), provided that such Investor Advisors are similarly bound by the confidentiality provisions set forth herein; (iii) to the extent that an Investor needs to disclose Confidential Information for the
protection of any of such Investor’s rights or interest against the Company, whether under this Agreement or otherwise; or (iv) to the disclosure of Confidential Information to a prospective transferee of securities which agrees to be
bound by the provisions of this Section in connection with the receipt of such Confidential Information. For clarification purposes, the information received from the Company in connection with the License and Development Agreement or Supply
Agreement between the Company and Medtronic shall be subject to the confidentiality and restrictions on use provisions as set forth in those respective agreements and not as set forth herein. 
 3.4 Meetings of the Board of Directors. The Company shall use all reasonable efforts to cause the Board of Directors to meet at least once in
every three (3) month period. 
  

 16. 

 3.5 Board Committees. 
 (a) Compensation Committee. The Company shall use all reasonable efforts to cause the Board of Directors to maintain a Compensation Committee of
the Board of Directors (the “Compensation Committee”), which shall be composed of not more than four (4) members of the Board of Directors. Two of the members of the Compensation Committee shall be the directors designated by
Boston Millennia Partners II Limited Partnership and Foundation Medical Partners L.P. (the “Series B Directors”) pursuant to the Voting Agreement, by and between the Company and certain stockholders of the Company, of even date
herewith (the “Voting Agreement”), one member of the Compensation Committee shall be the director designated by Arcapita Ventures I Limited (“Arcapita”) pursuant to the Voting Agreement and one member of the
Compensation Committee shall be one of the Common Directors (as defined in the Voting Agreement). 
 (b) Audit Committee. The Company
shall use all reasonable efforts to cause the Board of Directors to maintain an Audit Committee of the Board of Directors (the “Audit Committee”), which shall be composed of no more than three (3) directors, two of whom shall
be the Series B Directors; provided, however, that upon the closing of the Initial Offering, one Series B Director shall be required to resign from the Audit Committee. 
 3.6 Reservation of Common Stock. The Company will at all times reserve and keep available, solely for issuance and delivery upon the conversion of
the Preferred Stock, all Common Stock issuable from time to time upon such conversion. 
 3.7 Stock Vesting. Unless otherwise approved
by at least a majority of the disinterested non-officer members of the Board of Directors, all stock options and other stock equivalents issued after the date of this Agreement to founders, management, directors, or consultants shall be subject to
vesting as follows: (a) twenty-five percent (25%) of such stock shall vest at the end of the first year following the earlier of (i) the grant date of such option or other stock equivalent, or (ii) such person’s services
commencement date with the Company, and (b) the remaining seventy-five percent (75%) of such stock shall vest pro rata monthly over the remaining three (3) years. 
 3.8 Voting Agreement. 
 (a)
Subject to the approval of the Board of the Directors, the Company shall include in any stock option plan of the Company, or the related documents or agreements, a provision requiring each holder of the Company’s options or recipient of
Company stock awards or stock bonuses, who exercises such options for, or receives such stock awards or grants for shares of Common Stock, to, upon such exercise or receipt of such award or grant, become a party to the Voting Agreement. 

(b) Unless the Board of Directors determines otherwise in a particular instance, the Company shall require that each person or entity who
acquires shares of capital stock of the Company in an issuance approved by the Board of Directors or a committee thereof (other than share issuances covered by the provisions of Section 3.8(a) above), shall as a condition to receiving any such
shares of capital stock, become a party to the Voting Agreement by executing a counterpart signature page thereto or other instrument by which such person or entity agrees to be bound by and comply with the provisions of such Voting Agreement.

  

 17. 

 3.9 Key Man Insurance. The Company will use all reasonable efforts to obtain and maintain in full
force and effect term life insurance on the lives of certain key employees, naming the Company as beneficiary, with such employees and amount of coverage to be determined by the Board of Directors. 
 3.10 Proprietary Information and Inventions Agreement. The Company shall require all employees and consultants to execute and deliver the
Company’s standard Employee Proprietary Information and Inventions Agreement, or similar agreement to protect the Company’s intellectual property rights, and shall not, without the approval of a majority of the disinterested members of the
Board of Directors, amend or waive any material rights under any such agreement. 
 3.11 Directed Shares. 
 (a) In the event of the Company’s Initial Offering, the Company will use all reasonable efforts to require that the managing underwriter or
underwriters of such Initial Offering offer those Investors holding at least 300,000 shares of Series B Stock (“Series B Major Investors”) the right to purchase a number of shares (the “Directed Shares”) of the
Company’s Common Stock to be sold in the Initial Offering equal to five percent (5%) of the stock to be sold in the Initial Offering. The Directed Shares shall be offered to the Series B Major Investors on the same terms and at the same
price at which they are being offered to the public, pro-rata in proportion to the shares of Series B Stock held by each Series B Major Investor, subject in all cases to the requirements of applicable federal and state securities laws and rules of
any national securities exchange on which the Company’s stock is to be listed or quoted. 
 (b) The Company shall give twenty
(20) calendar days’ written notice to the Series B Major Investors of its intent to file a registration statement with the SEC to effect the Initial Offering of the Company’s Common Stock and the date proposed for such filing. At
least seven (7) calendar days prior to the filing of such registration statement, each Series B Major Investor will notify the Company in writing of its intent to exercise its rights to purchase such Directed Shares and the aggregate number of
such Directed Shares it intends to purchase. Any and all rights of a Series B Major Investor to purchase Directed Shares hereunder shall not be exercisable by such Series B Major Investor or enforceable against the Company until the date of the
closing of the Initial Offering. 
 (c) If not all of the Series B Major Investors elect to purchase their pro rata share of
the Directed Shares, then the Company shall promptly notify in writing the Series B Major Investors who do so elect and shall offer such Series B Major Investors the right to acquire such unsubscribed shares. Each Major Investor shall have five
(5) days after receipt of such notice to notify the Company of its election to purchase all or a portion of the unsubscribed shares. 
 (d) The rights of first refusal of each Series B Major Investor under this Section 3.11 may be transferred to the same parties, subject to the same restrictions as any transfer of registration rights pursuant to
Section 2.10. 
 (e) Notwithstanding the foregoing, all actions taken pursuant to this Agreement shall be made in accordance with
and to the extent permissible by all federal and state securities laws, including, without limitation, Rule 134 of the Securities Act, and all applicable rules and regulations promulgated by any national securities exchange on which the
Company’s stock is to be listed or quoted. Further, nothing in this Section 3.11 shall be construed to require the Company to take any action that it reasonably believes violates federal or state securities laws, including without
limitation the rules and regulations of the SEC as interpreted by SEC staff. 
  

 18. 

 3.12 Reimbursement. The Company will reimburse those members of the Company’s Board of
Directors who are elected by the holders of Series B Stock, voting as a separate class, and the member of the Company’s Board of Directors who is elected by the holders of the Series D Stock, voting as a separate class, for all reasonable
out-of-pocket expenses incurred by such members in connection with travel to and attendance of meetings of the Company’s Board of Directors and any committees thereof. 
 3.13 Form D. The Company shall timely file with the SEC a properly completed and executed Notice of Sale of Securities pursuant to Regulation D on
Form D (including any required amendments thereto) under Rule 506 promulgated under the Securities Act in connection with the transactions contemplated by the Purchase Agreement. 
 3.14 Taxes. 
 (a) The Company
shall use all reasonable efforts to cause the Series B Stock, Series C Stock and Series D Stock (and any stock into which the Series B Stock, Series C Stock and Series D Stock, as the case may be, is converted) to continue to constitute
“qualified small business stock” as defined in Section 1202(c) of the Code. The Company shall submit to its stockholders and to the Internal Revenue Service any reports that may be required under Section 1202(d)(1)(C) of the
Internal Revenue Code of 1986, as amended (the “Code”), and the related Treasury Regulations. In addition, within ten days after any Investor’s written request therefor, the Company shall deliver to such Investor a written
statement indicating whether such Investor’s interest in the Company constitutes “qualified small business stock” as defined in Section 1202(c) of the Code. In the event that less than all of the Investor’s interest in the
Company constitutes “qualified small business stock,” such written statement shall indicate the portion, if any, of such interest that does constitute “qualified small business stock,” and the portion, if any, of such interest
that would constitute “qualified small business stock,” if determination of whether stock constitutes “qualified small business stock,” were made by taking into account the modifications set forth in Section 1045(b)(4) of
the Code. 
 (b) The Company shall use best efforts to prevent becoming a “United States real property holding corporation”
as defined in Section 897(c)(2) of the Code and the Treasury Regulations thereunder. 
 3.15 Visitation Rights. 
 (a) So long as Medtronic continues to own stock of the Company, the Company shall allow one representative designated by Medtronic to attend all
meetings of the Company’s Board of Directors in a nonvoting capacity, and in connection therewith, the Company shall give such representative copies of all notices, minutes, consents and other materials, financial or otherwise, which the
Company provides to its Board of Directors; provided, however, that the Company reserves the right to exclude such representative from access to any material or meeting or portion thereof if the Company’s Board of Directors determines in
good faith that such exclusion is necessary (i) to preserve the attorney-client privilege, or (ii) to prevent a conflict of interest, or (iii) to prevent such representative’s participation in discussions relating to disputes
with Medtronic and/or its affiliates, or (iv) to prevent such representative’s participation in discussions of the Company’s relationship with Medtronic. The Board’s good faith decision, made based upon facts available at the
time of the exclusion and upon the advice of informed and qualified legal counsel, with respect to preserving attorney-client privilege or preventing a conflict of interest, shall be final and binding. The Company shall make reasonable efforts to
permit Medtronic’s representative to observe meetings of the Company’s Board of Directors by telephone if such designee is unable to attend in person. The Parties agree that Medtronic’s observer to the Company’s Board of
Directors shall be present solely for the purpose of observation and shall have no power to exert “control” on behalf of Medtronic as that term is defined in Rule 405 under the Securities Act. 
  

 19. 

 (b) So long as Guidant Investment Corporation (together with its Affiliated Parties, including
Guidant Foundation) continues to own stock of the Company, the Company shall allow one representative designated by Guidant Investment Corporation to attend all meetings of the Company’s Board of Directors in a nonvoting capacity, and in
connection therewith, the Company shall give such representative copies of all notices, minutes, consents and other materials, financial or otherwise, which the Company provides to its Board of Directors; provided, however, that the Company
reserves the right to exclude such representative from access to any material or meeting or portion thereof if the Company believes upon advice of counsel that such exclusion is reasonably necessary to preserve the attorney-client privilege or to
protect highly confidential information. The decision of the Board of Directors with respect to the privileged or confidential nature of such information shall be final and binding. 
 (c) So long as Johnson & Johnson Development Corporation (“JJDC”) (together with its Affiliated Parties) continues to
own stock of the Company, the Company shall allow one representative designated by JJDC to attend all meetings of the Company’s Board of Directors in a nonvoting capacity, and in connection therewith, the Company shall give such representative
copies of all notices, minutes, consents and other materials, financial or otherwise, which the Company provides to its Board of Directors; provided, however, that the Company reserves the right to exclude such representative from access to
any material or meeting or portion thereof if the Company believes upon advice of counsel that such exclusion is reasonably necessary to preserve the attorney-client privilege or to protect highly confidential information. The decision of the Board
of Directors with respect to the privileged or confidential nature of such information shall be final and binding. 
 (d) If at any
time Arcapita is no longer entitled to appoint a member to the Board of Directors but, at such time, continues to own stock of the Company, then from such time and for so long as Arcapita (together with its Affiliated Parties) continues to own stock
of the Company, the Company shall allow one representative designated by Arcapita to attend all meetings of the Company’s Board of Directors in a nonvoting capacity, and in connection therewith, the Company shall give such representative copies
of all notices, minutes, consents and other materials, financial or otherwise, which the Company provides to its Board of Directors; provided, however, that the Company reserves the right to exclude such representative from access to any
material or meeting or portion thereof if the Company believes upon advice of counsel that such exclusion is reasonably necessary to preserve the attorney-client privilege or to protect highly confidential information. The decision of the Board of
Directors with respect to the privileged or confidential nature of such information shall be final and binding. 
 3.16 Authorized Stock.
The Company shall at all times have authorized and reserved for issuance a sufficient number of shares of Common Stock to provide for the issuance of the Common Stock issuable or issued upon conversion of the Shares. 
 3.17 Termination of Covenants. All covenants of the Company contained in Section 3 of this Agreement (other than the provisions of Sections
3.1(a), 3.1(b), 3.2, 3.3, 3.10, 3.15, and 3.16) shall expire and terminate as to each Investor upon the closing of the Initial Offering. All covenants of the Company contained in Section 3 of this Agreement (other than the provisions of
Section 3.3) shall expire and terminate as to each Investor upon the earlier of (i) the closing of an Initial Offering in which the per share price is at least $3.00 (as adjusted for stock splits, dividends, recapitalizations and the like
after the date hereof) and the gross proceeds to the Company are at least Thirty Million Dollars ($30,000,000); or (ii) the closing of an “Asset Transfer” or “Acquisition”, each as defined in the Company’s Certificate
of Incorporation as in effect as of the date hereof (a “Change of Control”). 
  

 20. 

 SECTION 4. RIGHTS OF FIRST REFUSAL. 
 4.1 Subsequent Offerings. Subject to applicable securities laws, each Major Investor shall have a right of first refusal to purchase up to its
pro rata share of all Equity Securities, as defined below, that the Company may, from time to time, propose to sell, issue or exchange after the date of this Agreement, other than the Equity Securities excluded by Section 4.6 hereof.
Each Major Investor’s pro rata share is equal to the ratio of (a) the number of shares of the Company’s Common Stock (including all shares of Common Stock issuable or issued upon conversion of the Shares) which such Major
Investor is deemed to hold immediately prior to the issuance of such Equity Securities to (b) the total number of shares of the Company’s then outstanding Common Stock (including all shares of Common Stock issued or issuable upon
conversion of the Shares or upon the exercise of any outstanding warrants or options) immediately prior to the issuance of the Equity Securities. The term “Equity Securities” shall mean (i) any Common Stock, Preferred
Stock or other security of the Company, (ii) any security convertible into or exercisable or exchangeable for, with or without consideration, any Common Stock, Preferred Stock or other security (including any option to purchase such a
convertible security), (iii) any security carrying any warrant or right to subscribe to or purchase any Common Stock, Preferred Stock or other security or (iv) any such warrant or right. 
 4.2 Exercise of Rights. If the Company proposes to issue, sell or exchange any Equity Securities, it shall give each Major Investor a written
notice which shall (i) identify and describe the Equity Securities being issued, sold or exchanged, (ii) describe the price and other material terms upon which they are to be issued, sold or exchanged, and the number or amount of the
Equity Securities to be issued, sold or exchanged, (iii) identify the persons or entities (if known) to which or with which the Equity Securities are to be offered, issued, sold or exchanged, and (iv) offer to issue and sell to or exchange
with such Major Investor up to its pro rata share of such Equity Securities. Each Major Investor shall have thirty (30) days from the giving of such notice to agree to purchase all or a portion of its pro rata share of the Equity
Securities for the price and upon the terms and conditions specified in the notice by giving written notice to the Company and stating therein the quantity of Equity Securities to be purchased. Notwithstanding the foregoing, the Company shall not be
required to offer or sell such Equity Securities to any Major Investor who would cause the Company to be in violation of applicable federal or state securities laws by virtue of such offer or sale. 
 4.3 Issuance of Equity Securities to Other Persons. If not all of the Major Investors elect to purchase their full pro rata share of the
Equity Securities, then the Company shall promptly notify in writing the Major Investors who do so elect and shall offer each such Major Investor the right to acquire that portion of such unsubscribed shares as the number of shares initially
subscribed for by such Major Investor bears to the total number of shares initially subscribed for by all Major Investors. Each Major Investor shall have five (5) days after receipt of such notice to notify the Company of its election to
purchase all or a portion of the unsubscribed shares. If the Major Investors fail to exercise in full their rights of first refusal, the Company shall have ninety (90) days thereafter to sell the Equity Securities in respect of which the Major
Investors’ rights were not exercised, at a price and upon general terms and conditions not materially more favorable to the purchasers thereof than specified in the Company’s notice to the Major Investors pursuant to Section 4.2
hereof. If the Company has not sold such Equity Securities within ninety (90) days of the notice provided pursuant to Section 4.2, the Company shall not thereafter issue, sell or exchange any Equity Securities, without first offering such
securities to the Major Investors in the manner provided above. 
 4.4 Termination and Waiver of Rights of First Refusal. The rights
of first refusal established by this Section 4 shall not apply to, and shall terminate upon the earlier of (i) the closing of the Company’s Initial Offering or (ii) the closing of a Change of Control. The rights of first refusal
established by this Section 4 may be amended, or any provision waived with the written consent of Major Investors holding a majority of the Registrable Securities held by Major Investors; provided, however, that in the event an amendment
or waiver adversely affects the rights and/or obligations of any Major 

  

 21. 

 
Investor under this Section 4 in a manner materially different from the manner in which it affects the rights and/or obligations of each of the other
similarly situated Major Investors, such amendment shall also require the written consent of such adversely affected party or a majority in interest of such adversely affected parties. 
 4.5 Transfer of Rights of First Refusal. The rights of first refusal of each Major Investor under this Section 4 may be transferred to the
same parties, subject to the same restrictions as any transfer of registration rights pursuant to Section 2.10. 
 4.6 Excluded
Securities. The rights of first refusal established by this Section 4 shall have no application to any of the following Equity Securities: 
 (a) Up to an aggregate of six million seven hundred seventy-nine thousand four hundred ninety-one (6,779,491) shares of Common Stock (including shares of Common Stock underlying options, warrants or other stock purchase rights)
issued or to be issued after the Original Issue Date (as defined in the Company’s Certificate of Incorporation) to employees, officers or directors of, or consultants or advisors to the Company or any subsidiary, pursuant to stock purchase or
stock option plans or other arrangements that are approved by the Board of Directors; 
 (b) stock issued or issuable pursuant to any
rights or agreements, options, warrants or convertible securities outstanding as of the date of this Agreement; and stock issued pursuant to any such rights or agreements granted after the date of this Agreement, so long as the rights of first
refusal established by this Section 4 were complied with or were inapplicable pursuant to any provision of this Section 4.6 with respect to the initial sale or grant by the Company of such rights or agreements; 
 (c) shares of Common Stock issued in connection with any stock split, stock dividend or subdivision by the Company approved by the Board of
Directors; 
 (d) shares of Common Stock issued upon conversion of shares of the Company’s Preferred Stock; 
 (e) any Equity Securities that are issued by the Company pursuant to a registration statement filed under the Securities Act; and 
 (f) up to an aggregate of one million (1,000,000) (or such greater amount as may be approved by the Board of Directors, including both of the
Series B Directors, or by holders of a majority of the then outstanding shares of Preferred Stock, including at least fifty-five percent (55%) of the then outstanding shares of Series B Stock) shares of (i) any Equity Securities issued
pursuant to any equipment loan or leasing arrangement, real property leasing arrangement, or debt financing from a bank or similar financial or lending institution, (ii) any Equity Securities issued for consideration other than cash pursuant to
a merger, consolidation, acquisition or similar business combination, and (iii) any Equity Securities issued in connection with strategic transactions involving the Company and other entities, including (A) joint ventures, strategic
alliances, manufacturing, marketing or distribution arrangements or (B) technology transfer or development arrangements, in each case, provided that such transaction is approved by the Board of Directors. 
 SECTION 5. MISCELLANEOUS. 
 5.1 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without reference to the choice of law principles thereof. 
  

 22. 

 5.2 Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof
shall inure to the benefit of, and be binding upon, the parties hereto and their respective successors, assigns, heirs, executors, and administrators and shall inure to the benefit of and be enforceable by each person who shall be a holder of
Registrable Securities from time to time; provided, however, that prior to the receipt by the Company of adequate written notice of the transfer of any Registrable Securities specifying the full name and address of the transferee, the Company
may deem and treat the person listed as the holder of such shares in its records as the absolute owner and holder of such shares for all purposes, including the payment of dividends or any redemption price. The Company shall not assign this
Agreement or any of the Company’s rights or obligations hereunder without the prior written consent of the holders of a majority of the then-outstanding Registrable Securities and the holders of a majority of the then outstanding Demand
Registrable Securities. 
 5.3 Entire Agreement. This Agreement, the Exhibits and Schedules hereto, the Purchase Agreement, the other
Related Agreements (as defined in the Purchase Agreement) and the other documents delivered pursuant thereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be
liable or bound to any other in any manner by any oral or written representations, warranties, covenants and agreements except as specifically set forth herein and therein. Each party expressly represents and warrants that it is not relying on any
oral or written representations, warranties, covenants or agreements outside of this Agreement. 
 5.4 Severability. In the event one
or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and this
Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. 
 5.5 Amendment and
Waiver. 
 (a) Except as otherwise expressly provided herein, this Agreement may be amended or modified only upon the written
consent of the Company, the holders of a majority of the then-outstanding Registrable Securities and the holders of a majority of the then-outstanding Demand Registrable Securities; provided however, that in the event an amendment,
modification or waiver adversely affects the rights and/or obligations of any party under this Agreement in a manner materially different from the manner in which it affects the rights and/or obligations of the other parties, such amendment,
modification or waiver shall be binding on such adversely affected party only with the written consent of such adversely affected party. 
 (b) Except as otherwise expressly provided herein, the obligations of the Company and the rights of the Holders under this Agreement may be waived only with the written consent of the holders of a majority of the then-outstanding
Registrable Securities and the holders of a majority of the then-outstanding Demand Registrable Securities; provided however, that in the event a waiver adversely affects the rights and/or obligations of any party under this Agreement in a
manner materially different from the manner in which it affects the rights and/or obligations of the other parties, such waiver shall be binding on such adversely affected party only with the written consent of such adversely affected party.

 5.6 Delays or Omissions. It is agreed that no delay or omission to exercise any right, power, or remedy accruing to any party, upon
any breach, default or noncompliance by another party under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of any
similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any kind or character on any party’s part of any breach, default or noncompliance under the Agreement or any
waiver on such party’s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, by law, or otherwise
afforded to any party, shall be cumulative and not alternative. 
  

 23. 

 5.7 Notices. All notices required or permitted hereunder shall be in writing and shall be deemed
effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (c) five
(5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the Company at the address as set forth on the signature page hereof and to any Investor at the address appearing on the books of the Company or at such address as the Company, or such
party, respectively, may designate by ten (10) days advance written notice to the other parties hereto. Notwithstanding the foregoing, any notice delivered to Medtronic by means of confirmed electronic mail shall also be given to Medtronic by
one of the other means set forth above; provided, however, that that such additional confirmation notice may incorporate by reference information and documents sent to Medtronic via confirmed electronic mail delivered to addresses designated in
writing by Medtronic if such notice identifies the electronic mail address(es) to and from which such information and documents were sent and the date(s) and time(s) such confirmed electronic mail was delivered. 
 5.8 Titles and Subtitles. The titles of the sections and subsections of this Agreement are for convenience of reference only and are not to be
considered in construing this Agreement. 
 5.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if
the Company shall issue Equity Securities in accordance with Section 4.6(f) of this Agreement, any purchaser of such Equity Securities may become a party to this Agreement by executing and delivering an additional counterpart signature page to
this Agreement and shall be deemed an “Investor,” a “Holder” and a party, and, if applicable, a “Demand Holder,” hereunder. 
 5.10 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. 
 5.11 Aggregation of Stock. In determining the number of Demand Registrable Securities, Registrable Securities and Shares, as the case may be,
owned by an Investor for purposes of exercising rights under this Agreement, all Demand Registrable Securities, Registrable Securities and Shares, as the case may be, held by Affiliated Parties of such Investor shall be aggregated together (provided
that no shares shall be attributed to more than one entity or person within any such group of Affiliated Parties). 
 5.12 Pronouns.
All pronouns contained herein, and any variations thereof, shall be deemed to refer to the masculine, feminine or neutral, singular or plural, as to the identity of the parties hereto may require. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 24. 

 IN WITNESS WHEREOF, the parties hereto have executed
this AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 
  

			
	 COMPANY:
  
 CARDIOMEMS, INC.

		
	By:	 	 /s/ Jay S. Yadav

		 	Jay S. Yadav
		 	Acting Chief Executive Officer

			
		
	Address:	 	75 Fifth Street, N.W., Suite 440
		 	Atlanta, GA 30308

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	INVESTORS:
	
	BOSTON MILLENNIA PARTNERS II LIMITED PARTNERSHIP 
		
	By:	 	Glen Partners II Limited Partnership
		
	By:	 	 /s/ Martin J. Hernon

		 	Martin H. Hernon
		 	General Partner
	
	BOSTON MILLENNIA PARTNERS II-A LIMITED PARTNERSHIP 
		
	By:	 	Glen Partners II Limited Partnership
		
	By:	 	 /s/ Martin J. Hernon

		 	Martin H. Hernon
		 	General Partner
	
	BOSTON MILLENNIA PARTNERS GMBH & CO. KG 
		
	By:	 	Boston Millennia Verwaltungs GmbH
		
	By:	 	 /s/ Martin J. Hernon

		 	Martin H. Hernon
		 	Managing Director
	
	BOSTON MILLENNIA ASSOCIATES II PARTNERSHIP 
		
	By:	 	 /s/ Martin J. Hernon

		 	Martin H. Hernon
		 	General Partner
	
	STRATEGIC ADVISORS FUND LIMITED PARTNERSHIP 
		
	By:	 	Glen Partners II Limited Partnership,
		 	its General Partner
		
	By:	 	 /s/ Martin J. Hernon

		 	Martin H. Hernon
		 	General Partner

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	FOUNDATION MEDICAL PARTNERS, L.P.
		
	By:	 	Foundation Medical Managers, LLC
		
	By:	 	 /s/ Lee R. Wrubel

		 	Lee R. Wrubel, M.D.
		 	Managing Member

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	ARBORETUM VENTURES 1, LLC
		
	By:	 	 /s/ Jan Garfinkle

		 	Jan Garfinkle
		 	Managing Partner
	
	ARBORETUM VENTURES 1-A, LLC 
		
	By:	 	 /s/ Jan Garfinkle

		 	Jan Garfinkle
		 	Managing Partner

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	JOHNSON & JOHNSON DEVELOPMENT CORPORATION
		
	By:	 	 /s/ Denise L. Hudson

	Print Name:	 	Denise Hudson
	Title:	 	VP Strategic Operations
	
	RTK ASSOCIATES, LLC 
		
	By:	 	 /s/ Robert D. McNeil

	Print Name:	 	Robert D. McNeil
	Title:	 	Sole Member
	
	MARJORIE MCNEIL FINDLAY 
		
		 	 /s/ Marjorie M. Findlay

	
	GC&H INVESTMENTS , LLC 
		
	By:	 	 /s/ John L. Cardoza

		 	John L. Cardoza
		 	Managing Member

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	JOHN E. GALLAGHER, SR. AND CATHERINE T. GALLAGHER
		
		 	 /s/ John E. Gallagher, Sr.

		 	John E. Gallagher, Sr.
		
		 	 /s/ Catherine T. Gallagher

		 	Catherine T. Gallagher
	
	ANDREW W. GALLAGHER 
		
		 	 /s/ Andrew W. Gallagher

	
	THE GALLAGHER IRREVOCABLE TRUST 
		
	By:	 	 /s/ Andrew W. Gallagher

		 	Andrew W. Gallagher
		 	Chief Financial Officer

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

	
	RONALD LEVINE
	
	 /s/ Ronald Levine

	
	WILLIAM KNOPF
	
	  

	
	DAVID ALLIE
	
	  

	
	ALBERT PANZERI
	
	  

	
	AHMET SINAN GURSOY
	
	 /s/ Ahmet Sinan Gursoy

	
	WILLIAM WORTZMAN
	
	  

	
	JULIUS HOLLIS
	
	  

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	VIBA INVESTMENTS, LLC
		
	By:	 	 /s/ Brian Bailys

	Print Name:	 	Brian Bailys
	Title:	 	General Partner
	
	VISCONSI ENTERPRISE, LLC 
		
	By:	 	 /s/ Anthoni Visconsi II

	Print Name:	 	Anthoni Visconsi II
	Title:	 	Member
	
	 BRIAN BAILYS, TRUSTEE OF THE

ANN W. SIEGEL TRUST DATED
 SEPTEMBER 27, 2004 

		
	By:	 	 /s/ Brian Bailys

	Print Name:	 	Brian Bailys
	Title:	 	Trustee

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	GUIDANT CORPORATION
		
	By:	 	  

	Print Name:	 	  

	Title:	 	  

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	MEDTRONIC, INC.
		
	By:	 	 /s/ Michael D. Ellwein

	Print Name:	 	Michael D. Ellwein
	Title:	 	VP & CDO

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	ARCAPITA VENTURES I LIMITED
		
	By:	 	 /s/ John Huntz

	Print Name:	 	John Huntz
	Title:	 	Executive Director

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	SWARTZ FAMILY LIMITED PARTNERSHIP #4
		
	By:	 	 /s/ Harry A. Kopelman, M.D.

	Print Name:	 	Harry A. Kopelman, M.D.
	Title:	 	Partner, Swartz Family Limited Partnership #4

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

	
	CHARLES L. BROWN, III
	
	 /s/ Charles L. Brown III

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	EASTON CAPITAL PARTNERS, L.P.
		
	By:	 	ECP GP, LLC, its General Partner
	By:	 	ECP GP, Inc., Manager
		
	By:	 	 /s/ Francisco A. Garcia

		 	Authorized Signatory
	Print Name:	 	Francisco A. Garcia

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	LATTERMAN FAMILY LIMITED PARTNERSHIP
		
	By:
	 	 /s/ Earl Latterman

	Print Name:	 	Earl Latterman
	Title:	 	General Partner
	
	323 BOULEVARD ASSOCIATES
		
	By:	 	 /s/ Jack M. Friedman

	Print Name:	 	Jack M. Friedman
	Title:	 	Managing Partner

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

					
	INVESTORS:	  	
			
	Entity Name:	  	David E. Allie, M.D.	  	
	Signature:	  	 /s/ David E. Allie, M.D.
	  	
	Print Name:	  	David E. Allie, M.D.	  	
	Title:	  	Chief of Cardiothoracic & Endovascular Surgery	  	
		  	(if applicable)	  	

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

					
	INVESTORS:	  	
			
	Entity Name:	  	Bo & Pop LP	  	
	Signature:	  	 /s/ Jay Rosenfield
	  	
	Print Name:	  	Jay Rosenfield	  	
	Title:	  	G.P.	  	
		  	(if applicable)	  	

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

					
	INVESTORS:	  	
			
	Entity Name:	  	 Frank J. Criado, M.D.
	  	
	Signature:	  	/s/ Frank J. Criado, M.D.	  	
	Print Name:	  		  	
	Title:	  		  	
		  	(if applicable)	  	

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

					
	INVESTORS:	  	
			
	Entity Name:	  	Raul P. Esquivel	  	
	Signature:	  	 /s/ Raul P. Esquivel
	  	
	Print Name:	  	Raul P. Esquivel	  	
	Title:	  	  
	  	
		  	(if applicable)	  	

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

					
	INVESTORS:	  	
			
	Entity Name:	  	Julius Hollis	  	
	Signature:	  	 /s/ Julius Hollis
	  	
	Print Name:	  	Julius Hollis	  	
	Title:	  	  
	  	
		  	(if applicable)	  	

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	INVESTORS:
		
	Entity Name:	 	William D. Knopf
	Signature:	 	 /s/ William D. Knopf

	Print Name:	 	William D. Knopf
	Title:	 	  

		 	(if applicable)

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	INVESTORS:
		
	Entity Name:	 	David J. Moliterno
	Signature:	 	 /s/ David J. Moliterno

	Print Name:	 	  

	Title:	 	  

		 	(if applicable)

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	INVESTORS:
		
	Entity Name:	 	Rahman Family Trust
	Signature:	 	 /s/ Muhit Rahman

	Print Name:	 	Muhit Rahman
	Title:	 	 Trustee

		 	(if applicable)

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	INVESTORS:
		
	Entity Name:	 	  

	Signature:	 	 /s/ Janet M. Rosenfield

	Print Name:	 	Janet M. Rosenfield
	Title:	 	  

		 	(if applicable)

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

			
	INVESTORS:
		
	Entity Name:	 	  

	Signature:	 	 /s/ David R. Stern

	Print Name:	 	David R. Stern
	Title:	 	  

		 	(if applicable)

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

					
	INVESTORS:	  	
			
	Entity Name:	  	Marvin L. Woodall	  	
	Signature:	  	 /s/ Marvin L. Woodall
	  	
	Print Name:	  	Marvin L. Woodall	  	
	Title:	  	  
	  	
		  	(if applicable)	  	

 AMENDED AND RESTATED INVESTOR
RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 EXHIBIT A 
 SCHEDULE OF INVESTORS 
 SERIES A INVESTORS: 
 Akst, Hymie 
 Allie, David E. 
 Atlanta Cardiology Group, P.C. FBO W. Knopf MD FS: Furman-Selz P/A & Savings Plan UAD 1/1/93 
 Brian Bailys, Trustee of the Ann W. Siegel Trust dated September 27, 2004 
 Bajzer, Christopher Thomas and Kimberlee Ann
Bajzer 
 Baker, James A. 
 Criado, Frank J. 
 Curran, David James 
 Day, Raymond W. and Bonita S. 
 Eles, Gustav R. 
 Esquivel, Raul P. 
 Foster, III, William H. 
 Frank, Rimerman Investments XXXIII 
 Gallagher, Andrew William 
 John E. Gallagher Sr. & Catherine T.
Gallagher 
 Giannini, Kathleen 
 GC&H Investments 

Grube, Eberhard 
 Harpster, Howard W. 
 Jain, Suresh P. 
 Kresevic, Darrin L. 
 Lalouche, Kathleen J. 
 Levine, Ronald L. 
 Mark Wholey Family Limited Partnership 
 Mendlik, Patsy A. 
 Moliterno, David J. 
 Musarra, Lawrence C. 
 Ohki, Takao 
 Rahman Family Trust, 1996 
 Rosenfield, James 
 Rosenfield, Janet M. 
 SBV Investments, LLC 
 Shah, Rupa Jagmohan 
 Sites, Jr., John C. 
 Spencer, Timothy Ryan 
 Stern, David R. 
 Sutor, Ronald and Deborah 
 Swartz Family Limited Partnership #4 
 TekVest Capital Partners I 

VIBA Investments, LLC 
 AMENDED
AND RESTATED INVESTOR RIGHTS AGREEMENT 

 SERIES A INVESTORS: 
 Visconsi Enterprises, LLC 
 Woodall, Marvin 
 Yadav, Satya P. 
 SERIES B INVESTORS: 
 Boston Millennia Partners II Limited Partnership 
 Boston Millennia Partners
II-A Limited Partnership 
 Boston Millennia Partners GMBH & Co. KG 
 Boston Millennia Associates II Partnership 
 Strategic Advisors Fund Limited Partnership 
 Foundation Medical Partners L.P. 
 Guidant Investment Corporation 

Arboretum Ventures 1, LLC 
 Johnson & Johnson Development
Corporation 
 RTK Associates, LLC 
 Marjorie McNeil Findlay

 Ronald L. Levine 
 William D Knopf 
 David E. Allie 
 Albert Panzieri 
 Ahmet Sinan Gursoy 
 William Wortzman 
 Julius Hollis 
 VIBA Investments 
 Visconsi Enterprises, LLC 
 Andrew A. Gallagher 
 John E. Gallagher Sr. & Catherine T. Gallagher 
 The Gallagher
Irrevocable Trust 
 GC&H Investments, LLC 
 Brian Bailys,
Trustee of the Ann W. Siegel Trust dated September 27, 2004 
 Series C Investors: 
 Medtronic, Inc. 
 Boston Millennia Partners II Limited Partnership 
 Boston Millennia Partners II-A Limited Partnership 
 Boston Millennia Partners
GMBH & Co. KG 
 Boston Millennia Associates II Partnership 
 Strategic Advisors Fund Limited Partnership 
 Foundation Medical Partners L.P. 
 Guidant Investment Corporation 
 Arboretum Ventures 1, LLC 
 Johnson & Johnson Development Corporation 
 RTK Associates LLC 
 Andrew W. Gallagher 
 John E. Gallagher Sr. & Catherine T. Gallagher

 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 Series C Investors: 
 The Gallagher Irrevocable Trust 
 Swartz Family Limited Partnership #4 
 Series D Investors: 
 Arcapita Ventures I Limited 
 Medtronic, Inc. 
 Boston Millennia Partners II Limited Partnership 
 Boston Millennia Partners II-A Limited Partnership 
 Boston Millennia Partners
GMBH & Co. KG 
 Boston Millennia Associates II Partnership 
 Strategic Advisors Fund Limited Partnership 
 Foundation Medical Partners L.P. 
 Arboretum Ventures 1, LLC 
 Arboretum Ventures 1-A, LLC 
 Johnson & Johnson Development Corporation 
 RTK Associates LLC 
 Andrew W. Gallagher 
 John E. Gallagher Sr. & Catherine T. Gallagher

 The Gallagher Irrevocable Trust 
 Swartz Family Limited
Partnership #4 
 Ahmet Sinan Gursoy 
 Ronald Levine 

GC&H Investments, LLC 
 Charles L. Brown, III 
 Easton Hunt Capital Partners, L.P. 
 Latterman Family Limited Partnership

 323 Boulevard Associates 
 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]